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Summary 
C-reactive protein (CRP) is a highly sensitive but non-specific acute phase 
protein that is produced in the liver in response to injury, inflammation and 
disease. CRP has been by shown by several authors to be elevated in dogs with 
lymphoma (LSA) compared to healthy control dogs, however the findings of their 
small studies have suggested that CRP is too non-specific to be used in a clinical 
setting to monitor dogs with LSA that are receiving treatment with 
chemotherapy. Studies in the human literature have shown that CRP 
concentration is significantly affected by extent of disease and by the presence 
of clinical signs in patients with both non-Hodgkin’s and Hodgkin’s lymphoma, 
and it has been suggested that an elevated concentration of CRP at time of 
diagnosis carries a poorer prognosis. No veterinary studies to date have been 
large enough to investigate the effect of patient clinical parameters on CRP 
concentration, or to determine whether CRP concentration carries any 
prognostic significance. 
The aim of this study was to determine whether serum CRP was a clinically 
relevant biomarker in dogs with LSA using a large population. Specific aims 
included confirming if differences existed between the CRP concentration of 
healthy dogs and dogs with LSA, and determining if any patient variables had a 
relationship with CRP concentration. The effect on CRP concentration in dogs 
receiving chemotherapy treatment was investigated, with an aim to determine 
whether CRP could be used for categorisation of remission status. Finally, the 
role of CRP concentration as a prognostic indicator was investigated with respect 
to disease relapse and survival.  
This study included 59 control dogs and 73 dogs with LSA. Spare serum was 
prospectively harvested and stored at -70°C prior to batch analysis on an 
immunoturbidimetric assay (Pentra 400, Horiba ABX). Serial samples were 
obtained at time of diagnosis, throughout treatment with chemotherapy, at 
routine re-check appointments and at time of recrudescence of disease. Dogs 
with LSA were fully staged at time of diagnosis to determine the extent of 
disease and all dogs were assigned a WHO stage and substage. Of the dogs that 
received treatment with chemotherapy, a remission status (i.e. 
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complete/partial remission, stable disease or progressive disease) was assigned 
at each visit based on the subjective response to treatment from the palpation 
of peripheral lymph nodes. Patient clinical data was retrospectively obtained 
from both paper and electronic records. CRP was investigated as both a 
continuous and categorical variable, and categorisation was based on the degree 
of elevation of concentration. Significance was set at a p-value of ≤0.05. CRP 
concentration was deemed normal if ≤10 mg/L.  
Results suggest that serum CRP concentration is significantly higher at time of 
diagnosis in dogs with LSA compared to the control dogs, however not all dogs 
with LSA exhibit an elevated CRP concentration. CRP concentration returns to 
within normal limits for the majority of dogs following 4 weeks of treatment 
with chemotherapy. Of the patient variables investigated, WHO stage and 
substage, and pre-treatment albumin concentration were shown to be significant 
following univariate analysis. Significant differences between the median CRP 
concentration of the different remission statuses exists, however the overlap of 
ranges of CRP concentration in each group suggests that it could not be used to 
categorise remission status. The median CRP concentration at time of diagnosis 
is significantly higher than at time of relapse of disease; however CRP 
concentration does become elevated in most dogs at time of relapse. CRP 
concentration was not shown to be significantly elevated in the weeks leading up 
to relapse, indicating that this biomarker is not useful for predicting early 
relapse prior to recrudescence of disease becoming clinically apparent. Finally, 
results of the survival analysis revealed that pre-treatment CRP concentration is 
not a significant variable, however immunophenotype and WHO substage are.  
This is the largest study to date investigating CRP concentration in dogs with LSA 
and is the first study to suggest a relationship between CRP concentration at 
time of diagnosis and pre-treatment albumin, WHO stage and substage. Findings 
from this study have confirmed those of previous authors; for example CRP 
concentration becomes elevated in dogs with LSA both at time of diagnosis and 
at time of relapse of disease, and that immunophenotype and WHO substage 
carry prognostic significance. Although CRP concentration did not show any 
prognostic significance, there was a trend for those dogs with a moderate and 
marked elevation in CRP concentration (>30 mg/L) to have a reduced overall 
survival time. 
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1 Literature Review 
1.1 Canine lymphosarcoma 
 
1.1.1 Prevalence of canine lymphosarcoma 
Cancer is a major cause of death in dogs. Prevalence increases with age 
(Edwards et al., 2003), and one third of all tumours occur in patients greater 
than 9 years of age (Dobson et al., 2002). Lymphosarcoma (LSA, malignant 
lymphoma) is the most common neoplastic condition of the haemolymphatic 
system in this species, and accounts for 83% of all haematopoietic malignancies 
(Dobson, 2004, Vail et al., 2001). Reported annual incidence rates range from 
24-79 in 100,000 dogs (Dorn et al., 1967, Edwards et al., 2003, Teske et al., 
1994, Dobson et al., 2002). A study by Dobson et al (2002) looking at a UK 
population of insured dogs showed an age-standardised annual incidence rate of 
107 in 100,000 dogs, however the actual incidence rate may be even higher 
when the non-insured population is considered.  
1.1.2 Aetiology 
LSA is a round cell tumour that can develop in any lymphoreticular tissue and is 
characterized by a clonal expansion of lymphoid cells.  
 
Figure 1 Cytology from a canine lymph node infiltrated with a centroblastic lymphosarcoma 
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LSA occurs spontaneously in the dog and although the aetiology is largely 
unknown, it is likely to be multi-factorial.  
1.1.2.1  Sex and breed  
It is generally accepted that there is no sex predisposition for canine LSA, 
however an increased prevalence is reported amongst males in some studies 
(Dobson and Gorman, 1993, Merlo et al., 2008, Ponce et al., 2003a). A genetic 
predilection has been suggested with a number of breeds reported to be at 
higher risk including boxers, bulldogs, Scottish terriers, Basset hounds and 
bullmastiffs (Edwards et al., 2003, Vail and MacEwen, 2000, Onions, 1984). A 
familial incidence is reported in bullmastiffs and predisposition by heritable 
mutation of the tumour suppressor gene p53 has been identified (Veldhoen et 
al., 1998, Nasir and Argyle, 1999, Onions, 1984).  
1.1.2.2  Environmental factors 
Several environmental causes have been suggested including living in industrial 
areas, exposure to magnetic fields, and chemicals such as pesticides, paints and 
solvents (Hayes et al., 1991, Gavazza et al., 2001, Reif et al., 1995). However, 
studies suffer from selection bias and recall bias due to their retrospective case-
control design; hence no definitive environmental causes can thus far be listed.  
1.1.2.3  Viruses 
Several viral agents have been implicated in the pathogenesis and progression of 
different forms of human LSA including the Epstein-Barr virus (EBV), human T-
cell lymphoma virus type-1 (HTLV-1) and human immunodeficiency virus (HIV) 
(Bower et al., 2008, Shuh and Beilke, 2005, Gandhi et al., 2004). Recent 
veterinary literature suggests a possible gamma herpes viral pathogenesis for 
canine LSA (Milman et al., 2011, Huang et al., 2012), however, the significance 
of viral particles with properties similar to retroviruses in short-term cultures of 
canine LSA tissue is unclear (Tomley et al., 1983). Investigation into a viral 
aetiology of canine lymphoma is ongoing and as molecular biology techniques 
improve so may the likelihood of isolating a causative agent. 
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1.1.3 Patient presentation 
Dogs with LSA commonly present with an asymptomatic peripheral 
lymphadenopathy, however clinical signs may also include anorexia, lethargy, 
weight loss, polyuria, polydipsia and dyspnoea (Dobson and Gorman, 1993, 
Gavazza et al., 2009). The type and severity of clinical signs are often related to 
the anatomic site of the LSA and whether there are associated paraneoplastic 
syndromes such as hypercalcaemia (Dobson and Gorman, 1993, Weller et al., 
1982a).  
1.1.4 Obtaining a diagnosis 
Round cell tumours exfoliate cells readily and as such LSA is often diagnosed by 
cytological examination of samples obtained by fine needle aspirate biopsy 
(FNAB). In dogs with equivocal cytological results or where histopathological 
diagnosis would be preferred, excision of a lymph node or surgical biopsy of the 
affected organ is performed. In recent years, flow cytometry and polymerase 
chain reaction (PCR) assay techniques have been described to provide a more 
sensitive and specific diagnosis (Gibson et al., 2004, Lana et al., 2006, Reggeti 
and Bienzle, 2011).  
1.1.5 Characterisation of LSA 
LSA has been characterized and classified in many different ways including its 
anatomical location, morphological type, tumour grade and phenotype.   
1.1.5.1  Anatomical classification 
LSA is most commonly classified on the basis of anatomic location. The 
multicentric form occurs most frequently and is reported in more than 80% of 
dogs with the disease (Weller et al., 1982b, Gavazza et al., 2009). Other 
anatomic classifications include alimentary or gastrointestinal (GI), cranial 
mediastinal and cutaneous (Cotchin, 1984, Rallis et al., 1992). Extranodal forms 
are less commonly observed and some sites include the central nervous system 
(CNS), eye, nose and kidney (Rallis et al., 1992, Dobson and Gorman, 1993). 
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1.1.5.2  Morphological and grade classification 
Canine LSA is described as a spontaneous model for human non-Hodgkins 
lymphoma (NHL) (Teske, 1994). To allow this model to work the pathological 
classification of lymphoma in the dog has often been performed using human 
NHL classification systems. The Working Formulation was adopted in the 1980’s 
and grouped LSA into 4 grades based on cell morphology: low, intermediate, 
high, and miscellaneous (National Cancer Institute, 1982, Carter et al., 1986). 
This system is now largely obsolete, having been replaced by the updated Kiel 
classification (Stansfeld et al., 1988, Lennert and Feller, 1991) and the Revised 
European-American Classification of Lymphoma (REAL) system (Harris et al., 
1994). Both of these systems changed LSA classification to low or high grade and 
introduced the concept of classification based on molecular and genetic 
characteristics.  The most recent system has been proposed by the World Health 
Organisation (World Health Organization, 2008), where the REAL system has 
been revised and now groups LSA based on molecular, phenotypic and cytogenic 
characteristics. In veterinary medicine, the updated Kiel classification is 
currently considered the most useful for canine patients (Fournel-Fleury et al., 
1997, Ponce et al., 2010) 
These classification systems allow LSA to be given a “grade” according to its 
aggressiveness and features of malignancy. Tumour grading when performed 
using the updated Kiel classification considers the size of cell and the mitotic 
index (MI). Low grade LSAs have small sized cells with a low or medium MI and 
high grade LSAs have medium to large sized cells and a high MI (Ponce et al., 
2010). Most canine LSA are high grade large B-cell lymphomas of an 
immunoblastic or centroblastic polymorphic subtype (Dobson and Gorman, 1993, 
Greenlee et al., 1990, Ponce et al., 2010). 
High grade lymphomas progress more rapidly, but due to their high mitotic rate 
are highly responsive to treatment with chemotherapy and radiation therapy, 
and may rarely be curable (Vail et al., 2001, Chun, 2009). Low grade LSA is less 
common and incidence ranges from 11-26% of cases depending on the 
classification system used (Greenlee et al., 1990, Fournel-Fleury et al., 1997). 
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Low grade lymphomas usually progress much more slowly and are less responsive 
to drug therapy (Gear, 2009a, Carter et al., 1986). 
1.1.5.3  Immunophenotypic classification 
Leukocytes have surface antigen markers which are referred to by a cluster of 
differentiation (CD) number, with CD79a (B-cell) and CD3 (T-cell) commonly 
used in veterinary medicine for immunophenotyping canine LSA (Fontaine et al., 
2009, Ponce et al., 2003b). 
LSA is an oversimplified term used to describe a myriad of different pathological 
presentations of lymphoid neoplasia in the dog. This differs greatly from human 
medicine where LSA is classified very precisely both pathologically and 
immunophenotypically using a wide panel of markers. In human medicine the 
treatment given and the prognosis for the patient varies depending on their 
exact diagnosis. These markers are currently not available commercially for dogs 
but have become the subject of much veterinary research in recent times and 
may improve our understanding of this complex disease in the future. Currently, 
immunophenotyping can be performed using specific monoclonal antibodies to 
determine the antigens on a cell surface and several techniques have been 
described. Microscopic detection by immunohistochemistry (IHC) and 
immunocytochemistry (ICC) are the most widely available techniques and allow 
for concurrent assessment of cell morphology and tissue architecture. With 
these techniques interpretation is subjective and there is often limited 
quantification of antigen expression (Culmsee et al., 2001). Flow cytometry can 
be used to assess large numbers of cells by objective and defined criteria to 
yield robust results. This technique is being increasingly used in veterinary 
medicine as a wider range of monoclonal antibodies become more readily 
available allowing more subtle classification (Gibson et al., 2004, Reggeti and 
Bienzle, 2011). Whatever the technique used, canine LSA is most commonly 
classified as being B-cell or T-cell, however other immunophenotypic 
classifications are less commonly assigned including mixed B/T cell and null cell 
(natural killer (NK) cell) (Ponce et al., 2010).  
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Figure 2 Immunocytochemistry of a B-cell LSA showing negative staining with CD3 
antibodies and positive staining with CD79a antibodies 
  
The most common immunophenotype for canine LSA is B-cell (Dobson et al., 
2001, Ponce et al., 2010), however many low grade and all primary cutaneous 
LSAs are T-cell (Fontaine et al., 2009, Fournel-Fleury et al., 1997). When 
comparing high grade multicentric LSA, immunophenotyping has been shown to 
have prognostic importance and historically B-cell LSA has carried a better 
prognosis with improved survival times when compared with T-cell LSA 
(Greenlee et al., 1990, Ponce et al., 2004, Dobson et al., 2001, Marconato, 
2011). 
1.1.6 Clinical staging 
Following a diagnosis of LSA the patient is “staged” to determine the anatomical 
extent of the disease according to the World Health Organisation (WHO) system 
(Owen, 1980), which is outlined in Table 1, as this may influence treatment 
choice and can have prognostic significance. Staging usually includes a thorough 
clinical examination, complete blood count (CBC), serum biochemistry, 
urinalysis, thoracic radiography, abdominal ultrasonography and ultrasound-
guided FNAB of organs and internal lymph nodes if abnormalities are detected. 
Bone marrow cytology or histopathology is indicated particularly when 
haematologic abnormalities are seen (Flory et al., 2007). Computed tomography 
(CT) can be combined with functional positron emission tomography (PET) using 
radiolabelled tracers such as 18F-fluorodeoxyglucose (FDG) to allow the 
visualization of various metabolic processes within cancer cells. PET-CT forms an 
important part of the standard diagnostic and staging protocol in human patients 
with LSA and has been shown to have prognostic significance (Hutchings and 
CD3 -ve CD79a +ve 
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Barrington, 2009). Its use has been investigated in dogs with LSA and initial 
studies show promise of improved detection of disease and more complete 
staging of disease (Lawrence et al., 2010). Flory et al (2007) has highlighted a 
need for a standardized staging regime as stage migration can occur as more 
sensitive diagnostic procedures are introduced.  
Table 1 World Health Organisation (WHO) staging system in dogs with lymphoma (Owens, 
1981) 
Stage Description 
I Single lymph-node involvement 
II Regional lymph nodes (on one side of the diaphragm) 
III Generalised lymph node involvement (on both sides of the diaphragm) 
IV Liver and/or spleen involvement, ± stages I–III 
V Haematologic or bone marrow involvement, ± stages I-IV 
Substage a No clinical symptoms 
Substage b Clinical symptoms present 
 
Patients with a lower stage and without clinical signs generally carry a better 
prognosis than those with a higher stage and which are showing clinical signs of 
disease (Keller et al., 1993, Vail and MacEwen, 2000, Carter et al., 1986, Baskin 
et al., 2000), however there is disparity in the literature and several studies 
have shown no significant association between WHO stage and prognosis (Keller 
et al., 1993, Flory et al., 2007).  
1.1.7 Treatment and prognosis 
Regardless of WHO stage at time of diagnosis, without treatment most dogs with 
LSA will die of their disease within 4-6 weeks (Vail et al., 2001), and systemic 
treatment in the form of prednisolone or cytotoxic drugs is required to prolong 
survival (Dobson et al., 2001, Hahn et al., 1992, Chun, 2009). Patients with stage 
I or single site extranodal lymphoma may benefit from a local treatment such as 
surgical excision of the tumour or radiation therapy at the local site. For those 
patients with multicentric LSA, chemotherapy is the most common form of 
treatment and many protocols have been suggested. Treatment with 
prednisolone alone increases patient median survival time to only 1-2 months 
   
 
25
(Gear, 2009b, Vail et al., 2001). Multi-drug chemotherapy protocols produce 
higher response rates and longer survival times than single agent protocols (with 
the exception of doxorubicin) (Simon et al., 2008, Hahn et al., 1992, Chun, 
2009). Conventional chemotherapy protocols include the low dose COP 
(cyclophosphamide, vincristine, prednisolone) protocol and the CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisolone) protocol (Appendix 
1). Complete response is achieved in 60-90% of dogs on these protocols, with a 
median survival time of 6-12 months (Dobson et al., 2001, Kaiser et al., 2007, 
Vail et al., 2001, Chun, 2009). 
Half-body radiation therapy has also been used in combination with 
chemotherapy and early results suggest that this may produce significantly 
longer disease-free intervals and median survival times (Williams et al., 2004, 
Gustafson et al., 2004, Lurie et al., 2009). Radiation therapy is not commonly 
performed due to the limited number of linear accelerators in the UK and the 
high cost associated with this treatment modality.  
1.1.8 Monitoring and categorising response 
Monitoring the response to treatment is important in patients with LSA. To 
improve survival time, a change of chemotherapy protocol may be indicated in 
refractory cases or where there is evidence of tumour recrudescence.  For those 
patients with a peripheral lymphadenopathy, response to treatment is usually 
assessed by the attending veterinary surgeon palpating the lymph nodes and 
taking caliper measurements. Despite the objective measurement of lymph 
nodes, determining remission status is subjective. Variation in the recorded 
remission status of human patients with both Hodgkin’s (HL) and NHL, and 
canine patients with LSA has been shown depending on the monitoring methods 
used (Carde et al., 2002, Williams et al., 2005).  
1.1.8.1  RECIST guidelines 
The response evaluation criteria in solid tumours (RECIST) guidelines v1.1 
(Eisenhauer et al., 2009) were developed to standardize the assessment of 
tumour burden and the monitoring of response to treatment. These guidelines 
were initially developed for solid tumours but have been shown to be applicable 
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in the monitoring of LSA in people and dogs (Assouline et al., 2007, Vail et al., 
2010). Tumour response is recorded according to the following categories: 
• Complete response (CR): No detectable disease. 
• Partial response (PR): Target lesions reduced by >30% but <100%. 
• Stable disease (SD): <30% decrease and <20% increase in target lesions. 
• Progressive disease (PD): Target lesions increased by >20%. 
The guidelines state that a complete response should not be assigned until 4 
weeks of treatment has been given (Eisenhauer et al., 2009). 
1.1.8.2  Minimum residual disease 
Minimum residual disease (MRD) is the term used to indicate there are cells 
remaining within the lymph nodes that are resistant to therapy despite no 
clinical detection of gross disease. As these cells continue to multiply, tumour 
recrudescence or relapse will ultimately occur. Repeat cytology or flow 
cytometry on samples from clinically normal lymph nodes can reveal evidence of 
MRD in patients with LSA which may facilitate treatment modification (Williams 
et al., 2005); however these techniques are not sensitive. Recent advances in 
PCR based detection methods have allowed the quantification of MRD in canine 
LSA and may have prognostic significance (Thilakaratne et al., 2010, Yamazaki et 
al., 2008).  
For those patients with other anatomical forms of LSA, diagnostic imaging 
including ultrasonography and radiography is often used to monitor response to 
treatment, however these techniques may not be sensitive enough to show MRD 
when compared to advanced imaging techniques such as PET-CT (Zinzani et al., 
2006, Spaepen et al., 2001). Early results show that PET-CT may be sensitive in 
detecting MRD disease in dogs with LSA and in detecting early response and early 
recrudescence of disease (Lawrence et al., 2009, LeBlanc et al., 2009). However 
the financial implications to fee-paying clients, combined with the limited 
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availability of scanners and radio-isotopes, has stopped this technique from 
being widely adopted in veterinary medicine.   
1.2 The acute phase response 
 
The body has many homeostatic mechanisms in place to maintain an optimal 
internal environment. When subjected to tissue injury or immunological stress, 
the body responds with a rapid, complex and non-specific reaction known as the 
acute phase response (APR). The APR is part of the innate defense system of 
many different species including dogs and humans and occurs when disturbances 
in homeostasis give rise to systemic and metabolic changes (Eckersall and 
Conner, 1988, Gabay and Kushner, 1999, Heinrich et al., 1990, Kushner and 
Mackiewicz, 1993, Murata et al., 2004, Paltrinieri, 2007, Tecles et al., 2005). 
Causes include infection, tissue injury from surgery and trauma, malignant 
neoplasia and immunological disorders (Ebersole and Cappelli, 2000, Gabay and 
Kushner, 1999, Hogarth et al., 1997, Lin et al., 2000, Nakamura et al., 2008, 
Pepys, 1981, Tecles et al., 2005). 
1.2.1 Local and distant effects 
During the APR a local reaction occurs at the site of injury which includes blood 
vessel dilatation and leakage, platelet aggregation and clot formation and 
activation of granulocytes and mononuclear cells within the inflamed tissue 
(Kushner, 1982). These produce cytokines and inflammatory mediators which 
diffuse into the systemic circulation (Castell et al., 1990, Heinrich et al., 1990, 
Yamashita et al., 1994).  
1.2.1.1  Cytokines in the APR 
The most important cytokines appear to include interleukin-1 (IL-1), interleukin-
6 (IL-6) and tumour necrosis factor alpha (TNF-α) (Castell et al., 1989, Murata et 
al., 2004, Paltrinieri, 2007, Petersen et al., 2004, Yamashita et al., 1994). The 
cytokines mediate a systemic reaction which is characterised by fever, 
leukocytosis, increased synthesis of hormones (including insulin, cortisol and 
catecholamines), alterations in serum cations (decreased zinc and iron 
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concentrations), increased erythrocyte sedimentation rate, activation of the 
clotting cascade, metabolic changes, and the modulation of protein synthesis by 
hepatocytes. This hepatic modulation gives rise to a number of proteins 
collectively termed the acute phase proteins (APPs) (Eckersall, 1995, Gabay and 
Kushner, 1999, Kushner and Feldmann, 1978, Kushner, 1982). Although APP 
production is mainly hepatocyte-derived and driven by the action of the 
inflammatory cytokines on hepatocytes (Castell et al., 1990, Castell et al., 1989, 
Hurlimann et al., 1966, Kushner and Mackiewicz, 1993), extrahepatic production 
has also been described in tissues including kidney, intestine, lung, heart, 
spleen, testis, bone marrow and lymphocytes (Kalmovarin et al., 1991, Lecchi et 
al., 2009, Ramadori et al., 1985, Skovgaard et al., 2009). 
There are at least 15 different cytokines known to exist and these are composed 
of very small molecules with a very short half-life (Gruys et al., 2005). There are 
similarities between human and dog cytokines (Soller et al., 2007). The 
relationship between the different cytokines is complex, and studies have shown 
that there is an overlapping pathway of APP induction (Heinrich et al., 1990, Lin 
et al., 2000). Cytokines can network to combine with other cytokines to promote 
or augment the production of APPs or they can directly regulate the production 
of other cytokines and APPs (Gabay and Kushner, 1999, Ganapathi et al., 1991). 
1.2.1.2  IL-6, IL-1 and TNF-α 
IL-6 is the major regulator of APP production, having been shown to promote 
hepatic synthesis of all positive APPs, but in particular C-reactive protein (CRP) 
(Castell et al., 1990, Mackiewicz et al., 1991, Yamashita et al., 1994). IL-1 has a 
moderate effect on the synthesis of some APPs and inhibits the production of 
others; it also induces IL-6 (Ebersole and Cappelli, 2000, Gabay and Kushner, 
1999). TNF-α is the major stimulator of IL-1 and induces catabolism of the 
muscles allowing increased flow of amino acids to the liver (Gabay and Kushner, 
1999, Paltrinieri, 2007). 
1.2.2 The acute phase proteins 
APPs have been defined empirically by Kushner and Mackiewicz (1993) as 
proteins whose plasma concentrations change by more than 25% following an 
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inflammatory response. Kushner (1982) previously defined the positive APPs as 
those whose serum concentrations increase and includes CRP, serum amyloid A 
(SAA), haptoglobin (Hp), α-1 acid aminoglycoprotein (AGP) and ceruloplasmin 
(Cp) (Eckersall and Conner, 1988, Caspi et al., 1987). The term ‘negative’ APPs 
describes those whose serum concentrations decrease during the APR. This 
occurs as the body preferentially uses any available amino acids to build the 
positive APPs.  Examples include albumin and transferrin (Kushner, 1982, Tecles 
et al., 2009, Yamashita et al., 1994). Kushner (1982) further divided the positive 
APPs into 3 classes based on the magnitude of their response: Class I includes 
the proteins whose concentration have a 2-fold increase (Cp); Class II includes 
those whose concentration increases approximately 2- to 4-fold (AGP, Hp); and 
Class III includes those whose concentration increase several hundred fold (CRP, 
SAA). 
In both people and dogs the “major” positive APPs are CRP and SAA, and the 
“major” negative APP is albumin (Cerón et al., 2005, Kushner, 1982, Murata et 
al., 2004, Paltrinieri, 2007). There are species differences which occur however, 
and CRP for example is a major APP in dogs and humans but only a moderate 
APP in cats and horses (Cerón et al., 2005, Murata et al., 2004). 
1.2.3 C-reactive protein 
CRP was first described by Tillet and Francis (1930) and was so named because it 
exhibited a high binding affinity to the C-polysaccharide of Streptococcus 
pneumoniae. It has been shown in both man and dogs to rise in concentration as 
quickly as 4 hours following an inflammatory stimulus, to achieve its maximum 
concentration within 24-72 hours, and to have a doubling time of 8 hours. Its 
concentration rapidly declines within 24-36 hours once the inflammatory 
stimulus is removed (Caspi et al., 1987, Kushner and Mackiewicz, 1993, Pepys, 
1981).  
1.2.4 The role of the APPs 
The biological function of the individual APPs is still not fully understood. They 
are known to protect against infection, help repair damaged tissue, and regulate 
the immune and inflammatory response (Cerón et al., 2005). Several APPs also 
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have the ability to initiate and sustain inflammation as well as having an anti-
inflammatory effect (Gabay and Kushner, 1999, Murata et al., 2004). There is 
growing evidence to suggest that APPs can be produced by neoplastic tissue and 
may contribute to tumour development and progression (Chan et al., 2007, 
Kovacevic et al., 2008, Malle et al., 2009).  
1.3  The role of APPs as general biomarkers of disease 
 
A biomarker has been defined by the National Cancer Institute as “a biological 
molecule found in blood, other body fluids, or tissues that is a sign of a normal 
or abnormal process or of a condition or disease”. Although measuring APPs is 
highly non-specific due to the numerous conditions that can result in tissue 
injury or inflammation, its measurement is highly sensitive. Due to this high 
sensitivity, APPs have become extensively used as biomarkers in human medicine 
over the last few decades. They are a marker of infection and inflammation and 
have been shown to have prognostic importance in many diseases (Herishanu et 
al., 2007, Hogarth et al., 1997, Kompoti et al., 2008, Ebersole and Cappelli, 
2000). Several APPs including CRP have been shown to be elevated in human 
patients with a variety of malignancies and they have therefore gained 
popularity in the diagnosis and monitoring of different cancers (Beer et al., 
2008, Chan et al., 2007, Falconer et al., 1995, Yoshida et al., 2008). Pre-
operative CRP has been significantly associated with the pathological stage of 
disease and of disease progression in patients with solid malignant tumours 
(Yudoh et al., 1996, Crozier et al., 2007, Shimada et al., 2003, Koike et al., 
2008). 
1.3.1 Acute phase proteins and cancer 
Serum APPs have been widely investigated in both human and veterinary 
medicine. CRP, SAA and AGP are often elevated with neoplasia (Biran et al., 
1986, Falconer et al., 1994, Chan et al., 2007, Raynes and Cooper, 1983, 
Fournier et al., 2000, Duché et al., 2000, Fujita et al., 1999), however CRP 
appears to be the most useful systemic biomarker for cancer in humans. It is 
elevated in a wide variety of malignancies including NHL, HL, hepatocellular, 
colorectal, urinary bladder, pancreatic, breast, prostatic and gastric cancer and 
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is a predictor of recurrence of disease and of overall poor survival (Wieland et 
al., 2003, Beer et al., 2008, Yoshida et al., 2008, Crozier et al., 2007, Legouffe 
et al., 1998, Ito et al., 2006, Hashimoto et al., 2005). Similarly, CRP, AGP and 
SAA can become elevated in many canine malignancies including LSA, acute 
lymphoblastic leukaemia, and a variety of sarcomas and carcinomas (Nakamura 
et al., 2008, Tecles et al., 2005, Planellas et al., 2009). Of these canine APPs, 
CRP has been most widely investigated due to its widespread clinical application 
in human medicine. 
1.3.2 Current suggested biomarkers for human and canine LSA 
Biomarker analysis is widely used in the diagnosis and prognostication of human 
cancers including NHL (Kim, 2006, Khalifa et al., 2008). Using proteomic 
analysis, canine specific biomarkers have been identified that are capable of 
differentiating LSA patients from non-LSA patients, though currently it has not 
been determined whether these markers are suitable to monitor the response to 
treatment of previously diagnosed patients (Ratcliffe et al., 2009, Mian et al., 
2006).  
1.3.2.1  Cytokines as biomarkers 
Cytokines are altered in humans and dogs with breast, lung, gastric, renal and 
bone tumours, lymphoma and leukaemia, with high serum concentrations being 
associated with advanced stages of disease (Khalifa et al., 2008, Itoh et al., 
2009, Tsimberidou et al., 2008, Preti et al., 1997, Seymour et al., 1995). IL-6 is 
the most studied plasma cytokine and has been shown to promote the 
antitumour activity of macrophages to produce lymphokine-activated killer (LAK) 
calls and stimulate the production of CRP which binds to tumour cells and causes 
tumour cell lysis. IL-6 also prevents the apoptosis of neutrophils which aid the 
killing of tumour cells (Wang and Sun, 2009). The use of IL-6 as a biomarker in 
dogs may be limited as the measurement of plasma cytokines is difficult due to 
their short half-lives (Gabay and Kushner, 1999). Recent investigation of TNF-α 
in dogs with LSA has shown that the current assays commercially available for 
detection of human TNF-α may be of limited use in this species (Hofer et al., 
2011).   
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1.3.2.2  Tissue biomarkers 
Survivin is a member of the inhibitor of apoptosis protein family and has a role in 
tumour cell proliferation. Survivin expression is a negative prognostic indicator 
in both human and canine patients with lymphoma (Schlette et al., 2004, Adida 
et al., 2000, Rebhun et al., 2008). A current limitation of the use of survivin in 
veterinary patients is that biopsied tissue is required and there is limited 
availability of the test. 
1.3.2.3  Serum enzyme biomarkers 
Serum enzyme biomarkers such as lactate dehydrogenase (LDH) and thymidine 
kinase (TK) have prognostic significance in human and canine patients with LSA 
and may be capable of predicting recurrence of disease (Dumontet et al., 1999, 
Ferraris et al., 1979, Hallek et al., 1992, von Euler et al., 2004, Nakamura et al., 
1997). LDH is higher in canine patients with LSA when compared to normal or 
diseased dogs; however there is disparity in the literature as to whether there is 
a relationship between LDH levels and clinical stage or survival time (Marconato 
et al., 2009, Greenlee et al., 1990, Zanatta et al., 2003, von Euler et al., 2006, 
Nakamura et al., 1997, Marconato et al., 2010). Serum TK is elevated in canine 
patients with LSA and appears to have prognostic significance (von Euler et al., 
2004, von Euler and Eriksson, 2011). In a study by von Euler et al (2004) serum 
TK correlates with WHO stage and substage, and may be an early marker of 
relapse. Serum TK is potentially a very useful tumour biomarker in veterinary 
LSA patients, and recent development of an ELISA assay may allow full 
exploitation of its use in the near future (von Euler et al., 2006). 
1.3.3   The current role of CRP in human and canine LSA 
In human medicine, serum CRP concentration provides prognostic information 
for patients with NHL and HL. It is a significant marker for disease remission and 
relapse, and can be used as a predictor of overall survival (Herishanu et al., 
2007, Legouffe et al., 1998, McMillan et al., 2001, Wieland et al., 2003). Serum 
CRP concentration is similarly significantly elevated in dogs with LSA. This 
elevation decreases to within the normal reference range when the patient 
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achieves complete remission during treatment with chemotherapy (Mischke et 
al., 2007, Merlo et al., 2007, Nielsen et al., 2007). CRP becomes elevated at 
time of relapse though there is disparity in the literature over whether this 
elevation achieves statistical significance (Merlo et al., 2007, Nielsen et al., 
2007). The elevated concentration of serum CRP at time of relapse may be 
related to tumour burden (Merlo et al., 2007). If this is so, CRP would not be 
useful as an indicator of early relapse as serum concentration would only 
become elevated once tumour burden was significant and relapse was already 
clinically apparent.  
1.4 CRP assay 
 
The current assay for canine serum CRP is relatively rapid, cheap and readily 
available for general veterinary practitioners due to the development of 
immunoturbidimetric methodology (Eckersall et al., 1991, Kjelgaard-Hansen et 
al., 2003a), making it an ideal biomarker for dogs with LSA. Lipaemic, 
haemolytic or hyperbilirubinaemic serum may not be suitable for use in some 
assays including the enzyme-linked immunosorbent assays (ELISA) due to 
significant changes in the values of CRP obtained (Martinez-Subiela and Ceron, 
2005), however immunoturbidimetric assays can be much less affected and the 
change in CRP is often within an acceptable 10% limit (Tecles et al., 2007) . CRP 
has been shown to be a stable biomarker for analysis which can be successfully 
stored at -70°C for long periods and can be subjected to multiple freeze-thaw 
cycles without a decline in concentration (Hartweg et al., 2007, Aziz et al., 
2003). It is recommended that multiple samples be run at the same time to 
reduce interassay variability (Aziz et al., 2003).  Substantial variation in CRP 
concentration between dogs has been noted, as has individual dog variation in 
multiple measurements (Carney et al., 2011, Kjelgaard-Hansen et al., 2003b).  It 
has been suggested that a population-based reference range may be unsuitable 
for interpreting serum CRP concentrations in dogs due to the individual dog 
variation, and that comparison between serial results may be more appropriate 
(Kjelgaard-Hansen et al., 2003b, Carney et al., 2011).  
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1.5 Study Aims 
 
The aims of this retrospective study were to use a large population size and a 
large number of serial samples per case to:  
1) Investigate whether a relationship exists between serum CRP concentration 
and the different patient variables,  
2) Investigate whether serum CRP can be used as a clinical monitoring tool of 
remission status for dogs with LSA, and  
3) Assess if serum CRP has any prognostic significance i.e. determine whether a 
relationship exists between pre-treatment CRP and time to relapse and overall 
survival time.  
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2 Materials and Methods 
2.1 Study design 
 
This prospective study was performed with full ethical approval from the 
Department of Ethics and Welfare, University of Glasgow. Owners of dogs 
included in the study signed a consent form allowing excess biological materials 
to be retained by the University. A retrospective search of the records was 
performed to determine clinical data for the dogs included in the study.  All 
clinical data were stored in Access 2003 (Microsoft Inc, USA).  
2.1.1 Study population 
Untreated dogs with LSA that presented to the University of Glasgow’s Small 
Animal Hospital between 2004 and 2010 were eligible for recruitment onto the 
study. A diagnosis of LSA was confirmed by cytology or histopathology and 
immunophenotyping was performed by ICC or IHC using antibodies against CD3 
and CD79a. Tumour grade was assigned using the Updated Kiel classification 
(Lennert and Feller, 1991) and the WHO classification (World Health 
Organization, 2008).  
Clinical staging was performed on all dogs and a WHO stage and substage 
assigned (Owen, 1980). The minimum clinical database for all dogs included 
CBC, biochemistry analysis, abdominal ultrasonography and thoracic 
radiography. Computed tomography was performed when clinically appropriate. 
Splenic and hepatic cytology and bone marrow evaluation was performed to 
complete staging when deemed clinically important and when client finances 
allowed.  
2.1.2 Exclusion criteria 
Dogs were excluded from the study if they had concurrent infectious disease, if 
they had previously been treated for their LSA with surgery or chemotherapy, or 
if they did not have a serum sample obtained prior to treatment.  
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2.1.3 Initial induction treatment protocols 
Dogs were treated with standard multidrug chemotherapy protocols for LSA. The 
decision for protocol selection was guided by the degree of client compliance 
and by the client financial situation. Those dogs with a high grade LSA were 
treated with one of the following protocols: 
• CHOP/modified CHOP: cyclophosphamide, doxorubicin, vincristine and 
prednisolone +/- l-asparaginase. 
• Low dose (LD) COP: cyclophosphamide, vincristine and prednisolone. 
• ALP: asparaginase, lomustine and prednisolone. 
Dogs with low grade LSA were treated with chlorambucil and prednisolone. For 
those clients that did not want to treat their pet with chemotherapy, the option 
of steroids was made available, where dogs were treated with anti-inflammatory 
doses of prednisolone (1-2 mg/Kg once or twice daily). The owners were given 
the option of declining any form of treatment for their pet following diagnosis.   
All chemotherapy protocols included an induction and maintenance part; 
Appendix 1 describes the protocols in detail.  
2.1.4 Relapse or ‘rescue’ protocols 
At relapse, dogs were re-staged and reinduced with a rescue chemotherapy 
protocol. The rescue protocols included: 
• CHOP/modified CHOP 
• LD COP 
• ALP 
• DMAC: dexamethasone, melphalan, actinomycin-D and cytosine 
arabinoside. 
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• LMP: chlorambucil, methotrexate and prednisolone. 
L-asparaginase (400 iu/Kg or 10,000 iu/m2) was included as an initial induction 
agent in several dogs. Appendix 1 describes the rescue protocols in detail.  
2.1.5 Clinical assessment 
For those patients with peripheral lymphadenopathy, orthogonal measurements 
of all affected lymph nodes were obtained using calipers.  Dimensions of the 
internal medial iliac, mesenteric and mediastinal lymph nodes were measured by 
metric rule using ultrasonographic equipment.  Full staging was repeated at the 
time of tumour relapse or 1, 3, 6 and 12 months following the end of a 
chemotherapy protocol.  
 
Response to treatment was assessed at each visit and remission status was 
determined according to the RECIST guidelines v1.1 (Eisenhauer et al., 2009). CR 
was not assigned until 28 days post treatment. For analysis purposes dogs SD i.e. 
minimal change from the previous measurements, were classed as the remission 
status that preceded it to reflect most accurately the level of disease present.  
 
2.2 Determining the CRP concentration 
 
Serum samples were obtained when there was excess whole blood collected at 
the time of initial staging, prior to any dose of chemotherapy and at time of 
restage and relapse. 1-2mL of whole blood was collected by jugular 
venipuncture into serum tubes. Blood was allowed to clot for approximately 2 
hours at room temperature then centrifuged at 9,000 revolutions per minute for 
3 minutes. A minimum of 200µL serum was harvested and frozen at -70°C for 
batch analysis at a later date. It was noted if the samples were grossly 
haemolytic, lipaemic or hyperbilirubinaemic.  CRP concentration was measured 
using more than one assay type as the collection period spanned several years; 
during which improvements and modifications were made to the assay. Where 
spare serum was available, as many samples as possible were run again on the 
most recent assay, the Pentra 400 (Horiba ABX, UK). This was done by batch 
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analysis to reduce inter-assay variability. CRP concentrations were excluded if 
they were obtained when the patient was experiencing chemotherapy toxicities 
or concurrent infectious disease. 
Assay 1) 2004-2005, Solid-phase sandwich immunoassay (Canine CRP 
ELISA, Tridelta Development Ltd, Ireland), (Eckersall et al., 1989): 
This assay was previously validated to have a low within-run imprecision with 
intra-assay coefficients of variance (n=8) of 1.0% and 2.8% at mean control 
values of 18 mg/L and 74 mg/L respectively.  This assay also has an acceptable 
between-run imprecision with inter-assay coefficients of variance (n=11) of 
11.1% and 12.6% at mean control values of 19 mg/L and 75 mg/L of CRP 
respectively.   
Assay 2) 2005-2010, Immunoturbidimetric assay (Cobas Mira, Roche 
Diagnostics, UK), (Eckersall et al., 1991):  
This assay was previously validated to have a low within-run imprecision with 
intra-assay coefficients of variance (n=10) of 4.5% and 4.3% at mean control 
values of 37mg/L and 66mg/L of CRP respectively. This assay also has an 
acceptable between-run imprecision with inter-assay coefficients of variance 
(n=14) of 10% and 11% at mean control values of 42 mg/L and 102 mg/L of CRP 
respectively.   
Assay 3) 2010-present, Latex-enhanced immunoturbidimetric assay 
(Pentra 400, Horiba ABX, UK):  
This assay was validated to have a low within-run imprecision with intra-assay 
coefficients of variance (n=12) of 0.5 % and 1.2% at mean control values of 4 
mg/L and 30 mg/L of CRP respectively. This assay also has an acceptable 
between-run imprecision with inter-assay coefficients of variance (n=12) of 4.8% 
and 8.5% at mean control values of 4 mg/L and 30 mg/L of CRP respectively.  
A serum CRP concentration ≤10mg/L was deemed normal based on previous 
findings by Eckersall et al (1989). 
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2.3 Control population 
 
The control population comprised 59 dogs of various breeds which were used as 
blood donors. The dogs were aged between 2-8 years and all weighed >25Kg. 
They were deemed ‘healthy’ based on a 2 week history of no illness or injury, 
negative findings on clinical examination, normal CBC and no significant renal or 
hepatic changes on biochemistry analysis. Serum was harvested and frozen at     
-70°C for batch analysis on the Pentra 400 analyser (Horiba ABX, UK).  
5 dogs in the healthy control population had slightly elevated serum CRP 
concentrations (>10 mg/L but <17 mg/L) and 1 dog was an outlier with a CRP 
concentration of 30.5 mg/L. The history for these dogs was reviewed to ensure 
there was no underlying clinical cause for the elevated CRP. No cause was 
determined for any of the dogs and they were therefore left within the control 
group.   
2.4 Statistical methods 
 
Data are presented as mean ± standard deviation (SD) where normally 
distributed, as median [interquartile range (IQR)] where not normally 
distributed, or as a percentage of the group from which they were derived for 
categorical variables. Normality was tested with the Anderson-Darling (AD) test, 
where p ≥0.05 indicated normal distribution. Where the distribution of CRP was 
not normal, data were log transformed in an attempt to improve the assumption 
of Gaussian distribution and variance homogeneity. Parametric testing was 
performed on data that were normally distributed and non-parametric testing 
was performed on data that were not normally distributed.  
All statistical analyses were performed using Minitab v13 (Minitab Inc., USA), 
GraphPad Prism v5.04 (GraphPad Software Inc., USA) and Stata 10.1 (StataCorp., 
USA) statistical software. Statistical significance was set at a p-value ≤ 0.05. 
   
 
40
2.4.1 Descriptive analysis 
Descriptive statistics were generated for continuous data which included the 
number in each group (n), range, mean (95% confidence interval (CI)), SD, 
median (95% CI), and the IQR. Graphical representation of the data included bar 
charts and box-and-whisker plots (boxplots) where the box represents the IQR, 
the line within the box represents the median, and the whiskers represent the 
range. Stars beyond the whiskers represent outlier values.   
2.4.2 Comparison of assays 
The paired CRP concentrations from all patients were pooled and were assigned 
into 3 groups depending on the assays by which the values were obtained:  
• ELISA v Mira 
• ELISA v Pentra 
• Mira v Pentra 
Time-series plots were created for each patient that had >5 sets of paired data 
(Appendix 2). Differences in variance were investigated using Levene’s test. 
Correlation between the assays was determined using Spearman rank (SR) 
correlation.  The Bland-Altman test was performed to test the agreement 
between the different assays. Graphs were produced which plotted the 
difference between the 2 CRP measurements from each assay on the y-axis 
against the average of the 2 CRP measurements on the x-axis.  
2.4.3 Categorising CRP concentrations  
The distribution of CRP concentration was evaluated for both the control group 
and the study cohort, and 4 bands were selected based on the degree of CRP 
elevation. The bands were categorised using the following CRP ranges:  
• Normal: CRP = ≤10 mg/L,  
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• Mild elevation: CRP = >10 ≤30 mg/L,  
• Moderate elevation: CRP = >30 ≤80 mg/L,  
• Marked elevation: CRP = >80 mg/L.  
Due to the small numbers of dogs in each categorical grouping, the Normal and 
Mild (N+M) groups and the Moderate and Marked (M+M) groups were combined at 
times to facilitate statistical analysis.  
2.4.4 Investigating the differences between groups 
Proportional differences were investigated using the Fisher’s exact test when 
n<5 in one or more groups, and using the Chi-square test when n≥5 in all groups. 
Comparison of the medians in 3 or more groups was performed using the Kruskal-
Wallis (KW) test. Comparison of the medians of 2 groups was performed using 
the Mann-Whitney U (MW) test.   
Comparison of paired or matched data was performed using the paired t-test for 
normally distributed data and the Wilcoxon-signed rank (WSR) test for data that 
were not normally distributed.  
2.4.5 Investigating the relationship between groups 
Correlation between CRP and the different patient variables was performed 
using Pearson’s correlation for normally distributed data and the SR test on data 
that were not normally distributed.   
The relationship between CRP as a continuous outcome and the different patient 
variables was investigated using a general linear regression model. CRP data was 
log-transformed to improve the assumption of normal distribution. Categorical 
variables included site (generalised multicentric vs. not generalised 
multicentric), WHO stage (II-III vs. IV-V), WHO substage (‘a’ vs. ‘b’), 
immunophenotype (B-cell vs. T-cell) and continuous variables included albumin 
concentration.  Univariate analysis was performed initially, and all significant 
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variables were placed into the final multivariate model. Fitted-line plots were 
produced for each variable investigated in the univariate model and the 
transformation of residuals was performed to improve the model.  
Logistic regression was also performed to investigate CRP as a binary outcome 
(≤30 mg/L vs. >30 mg/L) with various predictor variables. Categorical predictor 
variables included site, WHO stage and sustage, immunophenotype (as described 
above) and albumin (hypoalbuminaemic vs. not hypoalbuminaemic). Significant 
predictor variables from univariate analysis were placed in the final model for 
multivariate analysis.  
2.4.6 Determining CRP concentration cut-off values 
Area under the receiver operator characteristic (AUROC) curve analysis was 
performed to generate a range of cut-off values.  The best cut-off value was 
deemed the one with the best balance between sensitivity and specificity, 
where sensitivity is the proportion of true positives which are correctly 
identified and specificity is the proportion of true negatives which are correctly 
identified.  
2.4.7 Survival analysis 
Survival differences were investigated using a logistic regression model with 
different binary outcomes (survival time ≤6 months vs. >6 months, dead vs. 
alive, death due to LSA vs. death due to other reasons, and relapsed vs. not 
relapsed) to produce a likelihood ratio. Continuous predictor variables including 
CRP, albumin and calcium were log-transformed to improve the assumption of 
normality. Categorical predictor variables included WHO stage (II-III vs. IV-V), 
substage (‘a’ vs. ‘b’), immunophenotype (B-cell vs. T-cell), site (generalised 
multicentric vs. not generalised multicentric), albumin (hypoalbuminaemic vs. 
not hypoalbuminaemic), calcium (hypercalcaemic vs. not hypercalcaemic) and 
CRP (≤30 mg/L vs. >30 mg/L). The significant variables from the univariate 
analysis were placed into the final model for multivariate logistic regression 
analysis.  
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Survival analysis was performed using a Kaplan-Meier product limit method. 
Overall survival time (OST) was defined as the number of days from first 
chemotherapy treatment to death, and time to first relapse (TFR) was defined 
as the number of days from first chemotherapy treatment to first episode of 
progressive disease (relapse of disease) in dogs that achieved partial or complete 
remission. Log-rank and Gehan-Breslow-Wilcoxon tests were used to determine 
whether the overall survival functions in two or more groups were equal. This 
was supplemented with a Cox proportional hazards model. Potential predictor 
variables included WHO Stage and substage, immunophenotype, albumin, and 
calcium. Survival curves were generated for the significant variables. Dogs were 
censored at the date of analysis if still alive. 
To remove the effect on survival of the different treatment regimes and to 
homogenise the population, dogs that received any treatment other than a 
CHOP-type protocol were excluded from the analyses. 
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3 Results 
3.1 Defining the final study population 
 
To exclude any confounding variables, and to maximise the number of samples 
that could be used for final statistical analysis, the agreement between the 
different CRP assays was investigated along with the effects of repeat freeze-
thaw cycles, of concurrent disease, and of previous glucocorticoid treatment. 
The results of this analysis determined the final population for analysis.   
3.1.1 Testing the agreement between assays: paired samples 
Due to modifications of the CRP assay over the study time period, many samples 
were run on more than 1 assay, providing paired CRP concentrations for time 
points from several dogs. The paired CRP concentrations from all dogs with LSA 
were assigned into 3 groups depending on the assays from which they were 
obtained: Pentra/Mira, Pentra/ELISA and Mira/ELISA. To allow visualisation of 
any patterns between the paired assays, time-series plots were created for each 
patient that had >5 sets of paired data (Appendix 2).  
3.1.1.1  Comparison of the Pentra and Mira assays 
Six dogs had >5 samples from several time points run on the Pentra and Mira 
assays. Taking each dog separately, statistical analysis using the WSR test 
showed a significant difference in median CRP concentration between assays in 
only 2 dogs (Table 2). Considering all paired samples for the Pentra and Mira 
assays together (n=95), there was no significant variance between them 
(Levene’s test p=0.17) and both assays significantly correlated (p<0.001), 
however this correlation was only moderate (rs =0.54). There was also no 
significant difference between the median CRP concentrations of the paired 
samples run on both these assays (MW test W=1853.0, p=0.11). In summary, the 
2 assays showed good agreement in most statistical analyses except for the WSR 
test in 2 out of 6 dogs.  
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Table 2 Results of Wilcoxon signed-rank test for paired samples on Pentra & Mira assays 
Dog ID n= W-Stat P-value 
1 18 106.0 0.38 
3 14 92.0 0.01* 
8 8 22.0 0.62 
61 11 26.0 0.56 
62 15 57.0 0.89 
67 10 55.0 0.006* 
* Indicates a significant difference 
 
3.1.1.2  Comparison of the Pentra and ELISA assays 
Seven dogs had >5 samples run on the Pentra and ELISA assays. For individual 
dogs, statistical analysis using the WSR test showed a significant difference 
between the median CRP concentrations between assays in 4 out of 7 dogs 
(Table 3). When considering all paired samples together (n=88), the CRP 
concentrations significantly correlated (rs=0.832, p<0.001) however there was 
significant variance between both assays (Levene’s test p=0.04) indicating poor 
agreement. There was significant difference between the median CRP 
concentrations obtained from the Pentra and ELISA assay (MW test W=474.0, 
p<0.001). In summary, the statistical analyses indicated poor agreement 
between assays.  
Table 3 Results of Wilcoxon signed-rank test for paired samples on Pentra & ELISA assays 
Dog ID n= W-Stat P-value 
1 18 100.0 0.54 
3 13 88.0 0.003* 
8 8 29.0 0.14 
43 8 36.0 0.01* 
44 5 15.0 0.06 
47 25 325.0 <0.001* 
52 12 78.0 0.003* 
* Indicates a significant difference 
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3.1.1.3  Comparison of the Mira and ELISA assays 
Only 3 dogs had >5 samples run on the Mira and ELISA assays. For each 
individual, statistical analysis using the WSR test showed significant difference 
between the median CRP concentrations between assays in 1 dog only (Table 4). 
Considering all paired samples together (n=51), there was no significant 
difference in the variance between them (Levene’s test p=0.31), and there was 
significant correlation of the assays (p<0.001), however this was only moderate 
(rs =0.59).There was no significant difference between the median CRP 
concentrations obtained from the Mira and ELISA assay (MW test W=485.0, 
p=0.10). In summary, the 2 assays showed good agreement except in the WSR 
test in 1 out of 3 dogs.  
Table 4 Results of Wilcoxon signed-rank test for paired samples on Mira & ELISA assays 
Dog ID n= W-Stat P-value 
1 27 120.5 0.10 
3 13 90.0 0.002* 
8 8 31.0 0.08 
* Indicates a significant difference 
 
3.1.1.4  Bland-Altman analysis 
Further comparison of the paired samples from the different assays was 
performed using the Bland-Altman method (Figure 4) where the difference 
between both CRP measurements on the y-axis was plotted against the average 
of the 2 CRP measurements on the x-axis. This analysis showed there was 
insufficient agreement between the ELISA and Pentra assays (bias = -7.06, 95% CI 
-33.31, 19.19) and the Mira and Pentra assays (bias = -4.09, 95% CI -58.32, 
50.14). The agreement between the Mira and ELISA assays was more acceptable 
(bias = 1.8, 95% CI -11.9, 15.5). 
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Figure 3 Bland-Altman plot of paired CRP concentrations on i) ELISA & Mira assays; ii) 
ELISA & Pentra assays; iii) Mira & Pentra assays 
 
These results confirmed that there was insufficient agreement between assays to 
be able to combine in a single data set the samples run on one assay with those 
run on a different assay. Therefore, as the Pentra analyser was the most current 
assay, and as the largest number of samples were run on this assay, the final 
population was taken from these samples. All dogs that had CRP concentrations 
obtained only on the ELISA or Mira assays were excluded from further statistical 
analysis.  
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3.1.2 Do multiple freeze-thaw cycles affect CRP? 
Many of the samples were run over time on multiple assays, and ultimately on 
the Pentra analyser which we had previously determined to be the assay of 
choice. It was therefore important to determine that the repeat freeze-thaw 
cycles did not cause significant degradation of the CRP proteins and 
consequently result in artificially low serum CRP concentrations.  All Pentra CRP 
concentrations available were placed into 2 groups: Group 1 included those 
samples that were run on the first freeze-thaw cycle (n=452) and Group 2 
included those samples that were run after multiple freeze-thaw cycles (n=117). 
Table 5 displays the descriptive statistics and Figure 5 shows that the 
distribution of CRP concentrations in both groups is similar. There was no 
significant difference between the median CRP concentrations of groups 1 and 2 
(MW test W=127417.5, p=0.38).  
Table 5 Descriptive statistics for CRP in the different freeze-thaw groups 
Group n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% CI) 
(mg/L) 
IQR 
(mg/L) 
1 452 0.0-294.0 20.4 (17.1-23.8) 36.1 7.8 (6.7-9.4) 3.4-19.9 
2 117 0.3-225.6 22.5 (16.0-29.0) 35.5 8.6 (6.0-12.3) 3.5-25.0 
       
3 57 0.41-273.7 51.2 (37.1-65.3) 53.1 34.7 (24.9-49.2) 18.1-67.0 
4 16 5.9-198.1 54.3 (27.0-81.6) 51.1 32.6 (22.2-67.9) 21.6-75.0 
       
5 242 0.0-160.4 10.3 (8.3-12.3) 15.9 5.3 (4.8-6.3) 2.4-12.5 
6 53 0.7-66.1 9.9 (6.4-13.3) 12.4 5.5 (4.1-6.8) 3.1-10.5 
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Figure 4 Boxplot of CRP in first thaw and multiple freeze-thaw cycles 
a. All samples: Group 1 (all 1st thaw samples) vs. Group 2 (all multiple freeze-thaw samples); 
b. High CRP concentration samples: Group 3 (pre-treatment 1st thaw samples) vs. Group 4 
(pre-treatment multiple freeze-thaw samples); c. Low CRP concentration samples: Group 5 
(complete remission 1st thaw samples) vs. Group 6 (complete remission multiple freeze-
thaw samples) 
 
 
 
a. 
b. 
c. 
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The effect of multiple freeze-thaw cycles on different extremes of CRP 
concentration was also investigated, using pre-treatment samples (high CRP 
concentrations) and samples from dogs in CR (low CRP concentrations). A further 
4 groups of Pentra CRP concentrations were allocated (Table 5): Group 3 
included pre-treatment samples run on the first thaw cycle (n=57) and Group 4 
included pre-treatment samples that were run on the Pentra assay following 
repeat freeze-thaw cycles (n=16). Group 5 included samples obtained from 
patients in CR following treatment and were run on the first freeze-thaw cycle 
(n=242) and Group 6 included samples from patients in CR which were run on the 
Pentra analyser following repeat freeze-thaw cycles (n=53).  There was a similar 
distribution of CRP concentrations in groups 3 and 4 and groups 5 and 6 (Figure 
5), with no significant difference in the medians of the 2 groups when analysed 
using the MW test (Group 3+4: W=2075.0, p=0.66; Group 5+6: W=35636.5, 
p=0.75).  
These analyses indicated that it was acceptable to use samples that had 
undergone multiple freeze-thaw cycles.  
3.1.3 Does concurrent disease affect pre-treatment CRP?  
Of the 83 dogs that were included in the analysis, 54 dogs (65%) had no 
concurrent disease (NCD) at time of presentation and 29 (35%) had concurrent 
disease (CD). The 29 dogs with concurrent disease were split into 2 groups (Table 
6): those with non-inflammatory concurrent disease (NICD, n=7, 24%), and those 
with inflammatory concurrent disease (ICD, n=22, 76%). Descriptive statistics for 
each group can be found in Table 7.  
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Table 6 List of concurrent diseases at time of diagnosis (non-inflammatory & inflammatory) 
Group Disease type n=      
Non-inflammatory Heart disease – heart murmur 2 
                      - endocardiosis 1 
                      - dilated cardiomyopathy 1 
                      - mitral valve disease 1 
 Chronic renal disease 1 
 Protein-losing enteropathy 1 
   
Inflammatory Osteoarthritis 6 
 Benign prostatic hyperplasia 3 
 Biopsy wound 3 
 Skin disease – atopic dermatitis 2 
                    - pruritus 1 
                    - sebaceous cyst 1 
 Inflammatory bowel disease 1 
 Otitis externa 1 
 Chronic pancreatitis 1 
 Periodontitis 1 
 Cystitis 1 
 Diarrhoea 1 
 
Table 7 Descriptive statistics of CRP in the different concurrent disease groups 
Group n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% CI) 
(mg/L) 
IQR 
(mg/L) 
NCD 54 0.4-273.7 61.3 (43.5-79.1) 65.2 33.8 (25.6-61.1) 18.7-92.0 
CD 29 2.4-94.4 34.2 (24.8-43.5) 24.7 30.6 (19.7-44.9) 11.6-53.7 
NICD 7 10.3-94.4 39.5 (11.9-67.0) 29.8 30.2 (17.4-72.7) 20.0-64.8 
ICD 22 2.4-72.7 32.5 (22.1-42.8) 23.4 31.7 (12.0-47.9) 9.8-52.9 
NCD = no concurrent disease, CD = concurrent disease, NICD = non-inflammatory 
concurrent disease, ICD = inflammatory concurrent disease 
 
Statistical analysis showed no significant difference between the median CRP 
concentration for dogs with NCD and those with CD (MW test W=2416, p=0.16). 
There was also no difference between the median CRP concentrations for the 
dogs with NCD, NCID and ICD (KW test H=2.23, d.f.=2, p=0.33).  
Since CRP concentration did not differ between groups, it was concluded that 
common non-inflammatory and inflammatory conditions did not significantly 
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affect CRP in dogs with LSA, and as such all dogs were kept in the study even if 
they presented with concurrent disease. 
3.1.4 Does steroid treatment affect pre-treatment CRP 
concentration? 
Of the 83 dogs that presented, 73 (88%) had received no previous steroid 
treatment (NPS) at time of presentation, and 10 (12%) had received previous 
glucocorticoid steroid treatment (PS) at a dose rate of 0.5-2 mg/Kg. The dogs 
who had received steroids were further split into 2 groups: previous steroid 
treatment for <7 days (PS<7d, n=6, 60%), and previous steroid treatment for >7 
days (PS>7d, n=4, 40%). Table 8 shows the descriptive statistics for all groups of 
dogs. 
Table 8 Descriptive statistics for CRP in the different remission groups 
Group n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% 
CI) 
(mg/L) 
IQR 
(mg/L) 
NPS 73 0.4-273.3 51.9 (39.7-64.1) 52.3 34.3 (27.1-45.4) 19.1-273.7 
PS 10 4.6-269.7 51.2 (-6.9-109.3) 81.2 24.0 (6.8-58.2) 7.0-53.3 
PS<7d 6 5.2-269.7 66.0 (-39.6-171.6) 100.6 32.9 (8.8-187.7) 12.7-97.5 
PS>7d 4 4.6-93.0 29.1 (-38.9-97.0) 42.7 9.4 (4.6-93.0) 5.3-93.0 
NPS = no previous steroids, PS = previous steroids, PS<7d = steroids for <7 days, PS>7d = 
previous steroids for >7 days 
 
There was no significant difference between the median CRP concentration for 
the NPS group compared to the PS group (MW test: W=3138.0, p=0.32). There 
was also no significant difference between the median CRP concentrations for 
the NPS group compared to the the PS<7d and PS>7d group (KW test: H=1.90, 
df=2, p=0.39).  
Although there was no significant difference detected between groups, the 
median CRP concentration for the PS>7d group appeared very different from the 
other groups and it was felt there may have been too small a sample size in this 
group to detect significance. A decision was therefore made to exclude all 10 
dogs that had received previous steroid treatment.  
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3.2 Demographic analysis 
 
3.2.1 Comparison of the control and study cohorts 
To determine whether the dogs included within the control group were similar to 
those included in the study group some basic statistics were performed.   
3.2.1.1  Control dogs 
Of the 59 dogs used as a normal control population, 15 breeds were represented 
(Figure 6), with greyhounds (n=25, 42%), Labrador retrievers (n=10, 17%), 
crossbreeds (n=5, 8%) and flatcoated retrievers (n=5, 8%) most prevalent. Thirty 
eight dogs (64%) were male (5 entire, 33 neutered) and 21 (36%) were female (5 
entire, 16 neutered), making a male:female ratio of 1.8:1. The age of dogs 
ranged from 2-10 years with a median age of 6 years (mean 5.7 ± 1.9 years). Age 
was not normally distributed within this group (p<0.005) and was positively 
skewed. 
 
Figure 5 Chart of breeds for the Control & Lymphoma (LSA) populations 
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3.2.1.2  Lymphoma dogs 
Of the 73 dogs with LSA included for final statistical analysis, 26 breeds were 
represented (Figure 6), with crossbreeds (n=13, 18%), Labrador retrievers (n=12, 
16%), boxers (n=6, 8%), golden retrievers (n=5, 7%), bullmastiffs, German 
shepherd dogs (GSD) and cocker spaniels (n=4, 5% respectively) most prevalent. 
Fifty dogs (68%) were male (21 entire, 29 neutered) and 23 (32%) were female 
(16 entire, 7 neutered), making a male:female ratio of 2.2:1. The age of the 
dogs ranged from 0.9-12.0 years with a median age of 7.3 years (mean 7 ± 2.6 
years). Age was normally distributed within this group (p=0.49).  
There was no statistical difference in the proportions of males and females 
between the control and LSA populations (chi-sq=0.25, d.f.=1, p=0.62). There 
was however a statistical difference in the distribution of ages between the 
control and LSA populations (chi-sq=23.5, d.f.=2, p<0.001), and a significant 
difference in the median ages (MW test: W=3167.5, p=0.0005), with the control 
group having a younger population of dogs.  
3.3 Further demographics of the study population 
 
3.3.1  Results of patient staging 
3.3.1.1  Anatomical location 
All dogs were clinically staged to determine the anatomical location of disease. 
The majority of dogs (n=60, 82%) presented with generalised multicentric 
disease. Other presentations included alimentary (n=4, 5%), mediastinal (n=3, 
4%), hepatosplenic, nasal and bilateral submandibular lymph node (SMLN) 
involvement (n=2, 3% respectively).   
Due to the low numbers of dogs in some groups, dogs were classified as being 
either ‘generalised multicentric’ (GM) which included those dogs with a true 
multicentric presentation (n=60) or ‘not generalised multicentric’ (NGM) which 
included those dogs with single site and extra-nodal presentation (n=12).  
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3.3.1.2  WHO stage and substage 
On the basis of clinical staging, dogs were assigned a World Health Organisation 
(WHO) stage and substage. No dogs had stage I LSA and therefore only stages II-V 
were represented in the study population.  
Five dogs (7%) were stage II (4 substage ‘a’, 1 substage ‘b’), 14 (19%) were stage 
III (10 substage ‘a’, 4 substage ‘b’), 28 (38%) dogs were stage IV (13 substage ‘a’, 
15 substage ‘b’) and 26 (36%) were stage V (6 substage ‘a’, 20 substage ‘b’). 
More dogs presented with clinical signs and therefore substage ‘b’ (n=50) was 
more prevalent than substage ‘a’ (n=23). Figure 7 shows the distribution of 
substages ‘a’ and ‘b’ across the different WHO stages. 
 
Figure 6 Bar chart of distribution of WHO substage a + b across the different WHO stages 
 
3.3.1.3  Immunophenotyping 
Immunophenotyping was available for 58 dogs (79%). Of these, 31 (53%) were T-
cell, 25 (43%) were B-cell, and 2 (4%) were null cell.  
3.3.1.4  Pre-treatment calcium 
Hypercalcaemia is a common paraneoplastic syndrome in dogs with LSA.  Pre-
treatment serum total calcium concentration was available for 72 dogs (99%) and 
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4.46 mmol/L with a median concentration of 2.57 mmol/L [2.4-2.7 mmol/L]. 
The normal laboratory reference is 2.34-3.0 mmol/L.  
A paraneoplastic hypercalcaemia was present in 10 dogs (14%), and the range of 
total calcium concentration for these dogs was 3.37-4.46 mmol/L (median 3.79 
mmol/L). Hypocalcaemia was observed in 9 dogs (13%) with a serum calcium 
range of 1.53-2.33 mmol/L (median 2.30 mmol/L). Total calcium is bound to the 
protein in blood and as such hypoproteinaemia can result in a concurrent 
hypocalcaemia. All hypocalcaemic dogs in this group had a concurrent 
hypoalbuminaemia (albumin concentration range 10-28 g/L).  
Ionised calcium (i.e. non-protein bound) was obtained for some patients that 
presented with hypercalcaemia; however this data was not consistently available 
to permit analysis. 
3.3.1.5 Pre-treatment albumin 
Pre-treatment serum albumin concentrations were available for 72 dogs (99%). 
The albumin concentration for all dogs ranged from 3-36 g/L with a median of 28 
g/L [25-32 g/L]. The normal laboratory reference is 29-36 g/L.  
Hypoalbuminaemia was present in 38 dogs (53%), with albumin concentrations 
ranging from 3-28 g/L (median 26 g/L). Albumin is a negative APP and 
concentrations decrease as the concentration of the positive APPs (e.g. CRP) 
increases. Of the hypoalbuminaemic dogs, 37 (97%) had CRP concentrations 
above the normal laboratory reference of 10.0 mg/L (range 14.0-273.7 mg/L, 
median 47.8 mg/L).  The SR correlation test showed the negative correlation 
between albumin and CRP was significant (r = -0.39, p=0.02). General linear 
regression analysis of these 2 variables also showed a significant relationship 
(T=2.57, p=0.01), however there was poor goodness of fit of the regression line 
(R2 = 8.6%, Figure 8) indicating that CRP accounted for only 8.6% of the variance 
in albumin concentration in this population of dogs with LSA. 
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Figure 7 Fitted-line plot for the linear regression analysis of albumin & C- reactive protein 
 
The association between albumin and certain clinical parameters including WHO 
stage, substage and immunophenotype was investigated using the MW test. Dogs 
with WHO stage IV-V (n=53) had a significantly lower median albumin 
concentration (median 27 g/L) compared to dogs with WHO stage II-III (n=19, 
median 32 g/L; W=1014.5, p<0.001), and dogs with substage ‘b’ (n=39) had a 
significantly lower median albumin concentration (median 27 g/L) compared to 
dogs with substage ‘a’ (n=33, median 30 g/L; W=1453.0, p=0.005). No significant 
difference was noted between dogs with B-cell LSA (n=24, median 29 g/L) and 
dogs with T-cell LSA (n=31, median 28 g/L; W=655.0, p=0.78). These results 
indicate that albumin concentration is influenced by WHO stage and substage.  
3.3.1.6  Initial treatment and relapse protocols 
Of the 73 dogs in the lymphoma group, 65 (89%) were administered some form of 
drug treatment and 8 (11%) were not treated upon owner request. 
Chemotherapy was the most popular treatment choice with 60 dogs (92%) being 
given a standard protocol. The majority of dogs (n=51, 87%) received a CHOP or 
modified CHOP protocol, but 4 (7%) were given a lomustine-based protocol and 3 
(5%) a LD-COP or modified LD-COP protocol. One dog was given a single dose of 
l-asparaginase, 1 dog received a chlorambucil-based protocol and the remaining 
5 dogs (8%) were treated with prednisolone only. Appendix 1 describes the 
different chemotherapy protocols. 
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Of the dogs that started chemotherapy treatment, 44 (73%) relapsed at some 
point during or after treatment with the initial protocol. A ‘rescue’ 
chemotherapy protocol was used in an attempt to re-induce remission of disease 
in 36 (82%) relapsed dogs. Of these dogs, 14 (39%) re-started a CHOP or modified 
CHOP protocol, 12 (33%) started the ALP protocol and 5 (14%) were treated using 
another standard protocol (single-agent L-asparaginase n=2; LD-COP n=1; LMP 
n=1; DMAC n=1). 
For the purpose of analysis, dogs were grouped according to the treatment they 
received: 
1. No treatment/prednisolone only (No-tx/pred only). 
2. CHOP-type protocol. 
3. Any other protocol (including LD-COP, modified LD-COP, ALP, 
chlorambucil/pred, single-agent l-asparaginase). 
3.3.1.7  Effect of chemotherapy on remission status  
The effect of chemotherapy on the 60 dogs that were treated was examined and 
of specific interest was the remission status achieved by week 4 of treatment. 
Dogs were excluded if they died or stopped treatment at or before week 4 of 
chemotherapy or if no remission data was available. A total of 47 dogs met the 
inclusion criteria. The majority of these dogs (83%, n=39) achieved CR by week 
4, 6 dogs (13%) achieved a PR and 2 dogs (4%) had PD.  
3.3.1.8  Time to first relapse (TFR) 
TFR ranged from 15-436 days, with a median of 105 days [55-241 days].  
3.3.1.9  Overall survival time (OST) 
At time of analysis, 8 dogs (11%) with LSA were censored as they were still alive. 
Sixty-five dogs (89%) in the study died or were euthanized due to LSA-related 
reasons. Of these, 52 (80%) had progressive disease and 8 (12%) had tumour- or 
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chemotherapy-related problems (3 had chemotherapy toxicosis, 2 had 
disseminated intravascular coagulation (DIC), 1 each had tumour-lysis syndrome, 
severe anaemia and severe disease-related symptoms including vomiting and 
diarrhoea). Three dogs (5%) died of other diseases (1 each from congestive heart 
failure, dilated cardiomyopathy and osteosarcoma). Two dogs (3%) died suddenly 
at home and for analysis purposes they were classified as having died from their 
LSA.     
OST was determined for all dogs. Dogs that did not receive treatment were 
censored at 0 days survival. OST for all dogs ranged from 0-2089 days, with a 
median survival time of 136 days [18-356 days].  
OST was determined for the different treatment groups (Table 9) and a boxplot 
showing the distribution was produced (Figure 9). 
Table 9 Overall survival time (OST) for dogs in the different treatment groups 
Treatment Group n (%) OST Range 
(days) 
 
Median OST 
(days) 
No-tx/pred only 13 (18) 0-41 0 
    
CHOP-type protocol 51 (70) 1-1720 198 
    
Any other protocol 9 (12) 28-2089 273 
 
 
Figure 8 Box-and-whisker plot of the distribution of overall survival time (OST) for the 
different treatment groups. 
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There was a significant difference between the median overall survival times for 
the dogs in the ‘no tx/pred only’ group compared to the ‘CHOP-type protocol’ 
group (MW test: W=123.5, p<0.001) and the ‘no tx/pred only’ group compared to 
the ‘any other protocol’ group (MW test: W=95.0, p=0.0003). There was no 
significant difference between the median OST for the ‘CHOP-type protocol’ 
group and the ‘any other protocol’ group (MW test: W=1507.5, p=0.33).  
Many dogs (n=36, 49%) in this study had a short survival time of only 0-3 months, 
with all untreated dogs appearing in this group (Figure 10). The next biggest 
survival group was those that survived >12 months (n=15, 21%). Ten dogs (14%) 
survived between <3 to 6 months, 5 (7%) survived >6 to 9 months and 7 (9%) 
survived >9-12 months.  
 
Figure 9 Bar chart of distribution of overall survival time (OST) categories for treated & 
untreated dogs 
 
3.4 CRP in normal dogs and dogs with LSA 
 
The laboratory normal reference range used in this study was 0-10 mg/L.  
 
3.4.1 Descriptive statistics for the control and LSA dogs  
CRP concentration demonstrated a high degree of variance in both the control 
dogs and those with LSA (25.7 and 2735.6 respectively), was positively skewed 
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(Figure 11) and was not normally distributed in either group (p<0.005). CRP was 
within the normal reference range for 54 (92%) of the control dogs and 10 (14%) 
of the dogs with LSA. The range of CRP concentration in the control group was 
0.1-30 mg/L, with the maximum CRP concentration being 3 times the upper limit 
of the normal reference range. Most dogs however (n=54, 92%) had CRP 
concentrations that were within reference. For the LSA dog group, the range of 
CRP concentrations was 0.4-273.7 mg/L, with the maximum CRP concentration 
being as much as 27 times the upper limit of the normal range. In this group only 
a small percentage of dogs (n=10, 14%) had serum CRP concentrations that were 
within normal reference. The majority of dogs with LSA (n=65, 89%) had CRP 
concentrations <100 mg/L (<10-fold increase). Outliers were identified for both 
groups: the control group had 5 outliers with CRP concentrations of 11.1, 12.5, 
13.4, 16.5 and 30.5 mg/L, and the LSA group had 5 outliers with CRP 
concentrations of 171.5, 174.7, 184.9, 198.1 and 273.7 mg/L. Table 10 shows 
the descriptive statistics for the control dogs and the dogs with LSA.  
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Figure 10 Histogram of CRP in a) healthy control dogs and b) dogs with lymphoma (LSA) 
Note 10-fold difference in CRP mg/L between Fig a. and Fig b. 
Table 10 Descriptive statistics for CRP in the control dogs & dogs with lymphoma (LSA) 
Group n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% CI) 
(mg/L) 
IQR 
(mg/L) 
Control 59 0.1-30.5 3.9 (2.6-5.2) 5.1 2.5 (1.1-3.9) 0.3-4.6 
       
LSA 73 0.4-273.7 51.2 (39.7-64.1) 52.3 34.3 (27.1-45.4) 19.1-67.0 
 
3.4.2 Does CRP concentration differ between normal and LSA 
dogs? 
There was a difference between the distribution of CRP in the control dogs and 
LSA dogs, as can be seen in Fig 12. The LSA group had a significantly higher 
median CRP (median 34.3 mg/L, W=2026.0, p<0.001) than the control group 
(median 2.5 mg/L).  
 
a.Control dogs 
b. Dogs with LSA 
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Figure 11 Boxplot of CRP in control dogs vs. dogs with lymphoma (pre-treatment) 
 
 
3.4.2.1  Does the degree of CRP elevation differ between normal 
and LSA dogs? 
As well as considering individual CRP concentrations, the degree of CRP 
elevation was also evaluated for normal dogs and dogs with LSA. CRP 
concentrations were placed into 4 different categories selected according to the 
degree of elevation and the distribution of concentrations (Table 11, Figure 13). 
Due to the low number of control dogs in some groups, analysis with the Chi-
square test could not be performed; therefore a 2x2 analysis with the Fisher’s 
exact test was performed on the Normal/Mild and the Moderate/Marked groups. 
This showed a significant difference between control and LSA dogs, suggesting 
that LSA affects the degree of elevation of CRP concentration (p<0.001).  
Table 11 Categories of CRP elevation with count and frequency in control & lymphoma 
(LSA) groups 
CRP Category CRP range (mg/L) Control dogs n (%) LSA dogs n (%) 
Normal ≤10 54 (91.5) 10 (13.7) 
Mild increase >10-30 4 (6.8) 21 (28.8) 
Moderate increase >30-80 1 (1.7) 29 (39.7) 
Marked increase  >80 0 / 0 13 (17.8) 
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Figure 12 Bar chart showing distribution of CRP categories 
 
3.4.3 The distribution of pre-treatment CRP concentration in the 
different treatment groups 
Descriptive statistics for the CRP concentrations in the different treatment 
groups were generated (Table 12) and a boxplot showing the distribution of CRP 
concentration in the treatment groups was produced (Figure 14).  
Table 12 Descriptive statistics for pre-treatment CRP concentration in the different 
treatment groups 
Treatment Group n (%) CRP Range 
(mg/L) 
 
Median CRP (95% CI) 
(mg/L) 
IQR 
(mg/L) 
No-tx/pred only* 13 (18) 2.9-273.7 47.8 (19.4-172.5) 19.0-173.1 
     
CHOP-type protocol 51 (70) 0.4-184.9 31.1 (26.1-44.3) 21.2-64.5 
     
Any other protocol 9 (12) 2.4-136.0 18.9 (3.4-118.2) 4.3-108.9 
* No-tx/pred only = no treatment/prednislone only 
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Figure 13 Box-and-whisker plots showing the distribution of pre-treatment CRP 
concentration in the different treatment groups 
 
There was no significant difference noted between the median CRP 
concentrations for the different treatment groups (KW test: H=2.25, p=0.32) and 
distribution of CRP was fairly similar between the 3 groups, however those dogs 
that did not start a chemotherapy protocol had the highest CRP concentrations.  
3.5 Investigating which variables influence CRP in dogs with LSA 
 
To investigate whether certain demographic and clinical parameters that are 
related to LSA influenced CRP concentrations, values at time of diagnosis (pre-
treatment) were investigated with regard to several patient variables including 
age, sex, breed, WHO stage and substage, site, immunophenotype, albumin and 
calcium.   
To allow a comparison of median CRP concentrations, age was categorised into 3 
groups (0-3 years, >3-7 years and >7 years), while others variables were 
categorised into 2 groups i.e. breed (pedigree and crossbreed), site (generalised-
multicentric and not generalised-multicentric), albumin (hypoalbuminaemic and 
not hypoalbuminaemic) and calcium (hypercalcaemic and not hypercalcaemic). 
Certain variables had too few dogs to allow statistical comparison, therefore no 
analysis was performed on tumour grade, and only dogs that were B- and T-cell 
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were investigated for immunophenotype. Table 13 shows the descriptive 
statistics for each categorical variable. 
Table 13 Descriptive statistics for CRP in the different patient variables 
Patient 
variable 
n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% 
CI) (mg/L) 
IQR 
(mg/L) 
Age: 0-3 years 6 20.0-74.1 41.3 (16.6-66.0) 23.5 30.9 (2.4-72.0) 22.9-69.6 
       >3-7 years 27 2.9-198.1 52.1 (31.1-73.2) 2.9 33.3 (18.2-65.0) 15.3-78.4 
       >7 years 40 0.4-273.7 53.3 (35.5-71.0) 55.5 35.9 (25.1-55.2) 21.2-64.6 
       
Breed:Pedigree 61 0.4-273.7 51.8 (37.8-65.8) 54.8 34.3 (26.7-42.1) 18.1-65.3 
           X-breed 12 20.4-133.4 52.3 (27.3-77.3) 39.4 43.3 (20.5-86.0) 20.4-86.2 
       
Sex: Male 50 0.4-198.1 53.5 (39.5-65.5) 45.8 37.5 (27.0-55.1) 21.2-70.6 
       Female 23 2.6-273.7 50.5 (22.3-78.8) 65.4 30.2 (12.9-50.4) 8.4-64.7 
       
Stage: II 5 0.41-33.3 13.1 (-3.7-29.8) 13.5 5.9 (0.4-33.3) 3.01-26.7 
          III 14 2.4-136.0 32.0 (9.1-54.9) 39.7 18.6 (3.4-32.2) 3.4-39.7 
          IV 28 8.4-198.1 67.2 (46.7-87.8) 53.0 53.4 (35.7 -71.4) 28.3-94.1 
          V 26 23.7-273.7 53.5 (30.6-76.4) 56.7 35.0 (25.8-58.2) 23.7-64.7 
          II-III 19 0.4-136.0 27.1 (10.0-44.1) 35.4 18.2 (5.3-28.9) 3.4-30.2 
          IV-V 54 2.9-273.7 60.6 (45.7-75.5) 54.7 38.5 (32.3-62.6) 25.0-73.0 
       
Substage: a 33 0.4-136.0 36.0 (23.5-48.5) 35.2 25.4 (16.1-35.3) 9.3-56.8 
                b 40 2.9-273.7 65.0 (45.7-84.3) 60.4 38.5 (32.5-65.4) 24.1-77.3 
       
Site: GM 60 2.4-273.7 55.9 (41.5-70.4) 56.0 32.9 (26.0-55.9) 19.0-72.0 
        NGM 13 0.4-78.4 33.1 (19.3-46.9) 22.8 34.3 (15.5-45.4) 13.0-46.0 
       
IPT: B-cell 25 2.9-184.9 51.6 (33.0-70.1) 44.9 33.3 (24.6-60.4) 21.8-70.8 
       T-cell 31 0.4-136.0 40.1 (29.0-51.1) 30.1 30.2 (21.2-46.8) 19.4-64.8 
       
Albumin: NHA 40 0.41-198.1 37.4 (24.2-50.7) 41.5 24.9 (18.5-32.4) 10.7-49.9 
               HA 32 3.1-273.7 69.1 (47.5-90.7) 3.1 53.7 (35.2-69.9) 28.3-87.3 
       
Calcium: NHC 62 0.41-273.7 49.2 (36.2-62.3) 51.3 33.8 (25.1-44.9) 17.5-64.7 
              HC 10 18-198.1 65.5 (22.0-109.0) 60.8 33.6 (21.2-108.8) 21.2-105.0 
X-breed = crossbreed, GM = generalised multicentric, NGM = non generalised multicentric, 
IPT = immunophenotype, NHA = not hypoalbuminaemic, HA = hypoalbuminaemic, NHC = 
not hypercalcaemic, HC = hypercalcaemic 
 
Distribution of CRP concentrations for the categorical variables was normal for 
only 4 groups according to the AD test: 0-3 year olds (p=0.06), crossbreeds 
(p=0.25), Stage II (p=0.27) and the ‘not generalised-multicentric’ group (p=0.65). 
CRP concentration was positively skewed for all variables. 
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3.5.1 Do the median CRP concentrations for the different clinical 
parameters differ? 
There was significant difference in the median CRP concentration for the 
different WHO stages, indicating that CRP was influenced by WHO stage (Table 
14). Initial comparison of grouped stages i.e. II-III and IV-V showed a significant 
difference between these 2 groups (H=14.9, d.f.=3, p=0.002). This difference 
was maintained when comparing the medians of each separate stage (H=14.9, 
d.f.=3, p=0.002). Further analysis was performed to compare each stage with 
the other stages. This showed a significant difference in the median CRP 
concentrations between stage II and IV (W=27.0, p=0.004), stage II and V 
(W=33.0, p=0.01), stage III and IV (W=199.0, =0.007), and stage III and V 
(W=210.0, p=0.03). There was no significance when comparing stage II and III 
(W=43.0, p=0.55) and stage IV and V (W=845.0, p=0.20).  
Other variables which influenced CRP concentration significantly included WHO 
substage and albumin, where dogs that were substage ‘b’ had a significantly 
higher median CRP concentration compared to those that were substage ‘a’ 
(W=976.0, p=0.007), and where those dogs with hypoalbuminaemia had a 
significantly higher median CRP concentration compared to those dogs that were 
not hypoalbuminaemic (W=1175.0, p=0.001). 
No other patient clinical parameters were found to influence CRP significantly as 
can be seen in Table 14. Figure 15 shows the distribution of CRP in the 
significant variable groups. 
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Table 14 Results of the statistical analysis of the different patient variables 
Kruskal-Wallis analysis variables Median (mg/L) 
 
 
H-stat d.f. p-value 
Age (0-3/>3-7/>7 years) 30.9/33.3/35.9 0.07 2 0.97 
Stage (II/III/IV/V) 5.9/18.6/53.4/35.0 14.9 3 0.002* 
Mann-Whitney analysis variables Median (mg/L) W-stat  p-value 
Sex (male/female) 37.5/30.2 751.0  0.24 
Breed (pedigree/crossbreed) 34.3/43.3 2227.0  0.66 
Stage (II-III/IV-V) 18.2/38.5 419.0  0.0004* 
         (II/III) 5.9/18.6 43.0  0.55 
         (II/IV) 5.9/53.4 27.0  0.004* 
         (II/V) 5.9/35.0 33.0  0.01* 
         (III/IV) 18.6/53.4 199.0  0.007* 
         (III/V) 18.6/35.0 210.0  0.03* 
         (IV/V) 53.4/35.0 845.0  0.20 
Substage (a/b) 25.4/38.5 976.0  0.007* 
Site (GM/NGM)^ 32.9/34.3 2282.0  0.38 
Immunophenotype (B-cell/T-cell) 33.3/30.2 756.0  0.48 
Albumin (non-/hypoalbuminaemic) 24.9/53.7 1175.0  0.001* 
Calcium (non-/hypercalcaemic 33.8/33.6 2207.0  0.37 
^GM = generalised multicentric. NGM = non-generalised multicentric disease. * indicates 
significant variables. 
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Figure 14 Box-and-whisker plots of CRP concentration 
a. WHO stage (II, III, IV & V); b. WHO substage (a & b); c. albumin status (not 
hypolbuminaemic & hypoalbuminaemic) 
 
 
 
 
c. 
b. 
a. 
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3.5.2 Is there a linear relationship between CRP concentration 
and the different clinical parameters?  
As well as comparing the effect of clinical parameters on CRP concentration by 
categorical methods, the effects of different patient variables on pre-treatment 
CRP were also investigated using general linear regression, as shown in Table 15. 
To improve the assumption of normality, the CRP concentrations were log 
transformed (logCRP) prior to analyses. Univariate analysis showed WHO stage, 
substage and albumin to be significant variables and Figure 16 shows the fitted 
line plots and regression equations for these (the residual plots for all significant 
variables can be seen in Appendix 3).  
Table 15 Results of univariate analysis using general linear regression 
Variable Coef 95% CI T-stat F-stat R2 (%) P-value 
Site (GM/NGM)# -0.11 -0.05,0.27 1.40 1.97 2.70 0.17 
WHO Stage (II-III/IV-V) -0.28 -0.40,-0.15 -4.52 20.43 22.34 <0.001* 
WHO Substage (a/b) -0.17 -0.29,-0.06 -3.03 9.17 11.44 0.003* 
Immunophenotype (B-/T-cell) 0.06 -0.07,0.19 0.95 0.90 1.64 0.35 
Albumin (g/L) -0.03 -0.05,-0.01 -3.36 11.32 13.92 0.001* 
#GM = generalised-multicentric, NGM = not generalised-multicentric; * indicates significant 
variables 
 
Both WHO stage and substage were positively correlated with logCRP and as 
stage migrated from II-III to IV-V and substage migrated from ‘a’ to ‘b’ the 
logCRP increased. Albumin was negatively correlated and its concentration 
decreased as logCRP increased.  
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Figure 15 Fitted-line plots and regression equations for log-transformed CRP (logCRP) vs. 
a) WHO stage, b) WHO substage, c) albumin 
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Multivariate analysis was performed using the significant variables from the 
univariate analysis and only WHO stage retained significance (p=0.006, T=-2.86, 
F=8.19, R2 28.3%). The low R2 value for the final model indicates that WHO stage 
only accounts for some of the elevation in CRP concentration and is not the only 
contributing factor.   
3.5.3 Investigating the strength of association between the 
clinical variables and CRP concentration  
The association of clinical variables with CRP was investigated as a binary 
outcome (≤30 mg/L and >30 mg/L) using logistic regression. The 3 predictors 
which were statistically significant were: 
1. WHO stage IV-V compared to stage II-III was 6.09 times (95% CI 1.89-19.67) 
more likely to result in a CRP concentration >30 mg/L (p=0.002). 
2. WHO substage ‘b’ compared to substage ‘a’ was 3.17 times (95% CI 1.20-
8.32) more likely to result in a CRP concentration >30 mg/L (p=0.02). 
3. Hypoalbuminaemia compared to non-hypoalbuminaemia was 2.74 times 
(95% CI 1.05-7.18) more likely to result in a CRP concentration >30 mg/L 
(p=0.04). 
These 3 variables were tested in a multivariate model (with CRP categorised as 
the same binary outcome) and WHO stage retained significance, where stage IV-
V compared to stage II-III was 4.07 times (95% CI 1.11-14.99) more likely to 
result in a CRP concentration >30 mg/L (p=0.03).  
3.6 The effect of LSA remission status on CRP concentration 
 
The test whether CRP concentration could act as a potential biomarker for 
remission status in dogs receiving chemotherapy for LSA, pre-treatment (Pre-TX) 
CRP concentration was used as baseline as it represented the CRP concentrations 
at the time of diagnosis. The remission statuses investigated included CR, PR and 
PD. 
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3.6.1  Does CRP concentration normalise following treatment with 
chemotherapy? 
The effect of chemotherapy on CRP concentration at week 4 of chemotherapy 
was investigated. Dogs were excluded from analysis if they died or had PD at 
week 4 of chemotherapy, or if no further follow-up CRP concentrations were 
available after the Pre-Tx value. CRP concentrations were excluded if they were 
obtained at times of chemotherapy toxicity, and where possible, the next 
available CRP concentration was used. 41 dogs met the inclusion criteria, and of 
these dogs, 39 (95%) achieved CR, and 2 (5%) achieved PR by week 4 of 
treatment with chemotherapy. Of the dogs that achieved CR, 32 (82%) had CRP 
concentrations that were within the normal reference range by week 4 (range 
0.2-44.9 mg/L, median 3.7 mg/L). Of the dogs that achieved a PR, both had CRP 
concentrations within the normal reference range (range 4.4-8.5 mg/L, median 
6.5 mg/L) by week 4. Of the dogs that achieved CR, the CRP concentration at 
time of diagnosis was normal in 5 dogs (13%) and elevated in 34 dogs (87%). The 
range of CRP concentration for all dogs in this group was 0.4-184.9 mg/L and the 
median CRP concentration was 28.7 mg/L. The elevation in CRP concentration in 
the pre-treatment group was mild in 15 dogs, moderate in 13 dogs and marked in 
6 dogs.  Of the dogs that only achieved PR by week 4 of treatment, both had a 
CRP concentration that was elevated at time of diagnosis (range 22.5-78.4 mg/L, 
median 50.5 mg/L). The elevation in CRP concentration in this group was mild in 
1 dog and moderate in the second dog. Figure 17 shows a boxplot of the Pre-Tx 
CRP concentrations vs. the CRP concentrations at week 4 post treatment for the 
dogs in CR and PR.  
 
 
   
 
74
 
Figure 16 Box-and-whisker plot of CRP concentration at pre-treatment vs. week 4 post 
treatment  
a. Dogs in complete remission (CR) at week 4; b. Dogs in partial remission (PR) at week 4 
 
3.6.2 How does the CRP concentration differ between the 
different remission status groups 
A remission status was recorded at every patient visit. Where a CRP 
concentration was available, this was pooled into the appropriate remission 
status group. CRP concentrations were excluded if they were obtained at times 
of concurrent disease or chemotherapy toxicity. The remission groups included 
the results from all 73 patients with LSA, and descriptive statistics were 
generated (Table 16).  
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Table 16 Descriptive statistics for CRP in the different remission status groups 
Group n= Range 
(mg/L) 
 
Mean (95% CI) 
(mg/L) 
SD Median (95% CI) 
(mg/L) 
IQR 
(mg/L) 
Variance 
Pre-Tx 73 0.4-273.7 51.2 (39.7-64.1) 52.3 34.3 (27.1-45.4) 19.1-67.0 2736 
        
CR 311 0.0-160.4 10.0 (8.4-11.7) 14.8 5.5 (5.0-6.3) 2.8-10.9 219 
        
PR 62 0.0-95.5 9.7 (6.2-13.1) 13.6 4.6 (3.3-9.4) 2.2-13.5 185 
        
PD 118 0.2-294.0 36.6 (27.2-46.0) 51.7 14.3 (11.8-21.6) 5.8-49.1 2672 
 
CRP was positively skewed for all groups and was not normally distributed (AD 
test p<0.005). A boxplot of each group showed there was a wider spread of CRP 
concentrations and higher medians in the Pre-Tx and PD groups. Each group had 
outliers (Figure 18).  
 
Figure 17 Box-and-whisker plot of serum CRP concentrations of the control dogs and dogs 
with lymphoma in different remission statuses 
 
3.6.3 Does the absolute CRP concentration differ with remission 
status? 
The KW test was performed to compare the median CRP concentrations of the 
control group with that of the LSA dogs at each different remission status (using 
all CRP concentrations available for each remission status). This analysis 
confirmed there was a significant difference between the groups (H=128.3, 
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d.f.=3, p<0.001).  To determine where the precise differences occurred, the MW 
test was performed looking at each pair of remission status groups (Table 17).  
Table 17 Results of analysis with the Mann-Whitney-U test comparing median CRP 
concentrations of the control group and the groups of different remission statuses 
Analysis Groups Median CRP (mg/L) W-stat P-value 
Control/CR 2.5/5.5 7006.0 <0.001* 
Control/PR 2.5/4.6 2903.0 0.0002* 
Control/PD 2.5/14.3 2704.5 <0.001* 
    
Pre-Tx/CR 34.3/5.5 22546.5 <0.001* 
Pre-Tx/PR 34.3/5.5 6709.0 <0.001* 
Pre-Tx/PD 34.3/14.3 8336.5 0.0003* 
    
CR/PR 5.5/4.6 60016.0 0.68 
CR/PD 5.5/14.3 60055.5 <0.001* 
    
PR/PD 4.6/14.3 4028.5 <0.001* 
* indicates a significant result 
 
This analysis showed there were significant differences in median CRP of all 
groups except between the CR and PR group (p=0.68). Since CRP differed 
significantly between the remission statuses for all dogs in the study population, 
changes in CRP concentration for individual dogs over the course of treatment 
(i.e. assessment of within-dog variation) were also investigated.  
3.6.4  Does the CRP concentration differ with remission status 
within individual patients? 
3.6.4.1  Pre-treatment compared to complete remission 
For 43 dogs, statistical analysis was repeated using WSR test comparing each 
dogs’ Pre-Tx CRP concentration (range 0.405-269.7 mg/L, median 30.21 mg/L) 
with their first reported CRP concentration in CR (range 0.0-44.9 mg/L, median 
3.73 mg/L). This analysis showed a significant difference in the median CRP 
concentration between these 2 groups (W=902.0, p<0.001) which confirmed the 
results for the whole population in section 3.6.2.  
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3.6.4.2  Complete remission compared to partial remission 
To determine whether a difference between CR and PR could be detected on an 
individual dog basis, the WSR test was repeated for 26 dogs comparing a CRP 
concentration in PR (range 0.0-147.5 mg/L, median 5.96 mg/L) with their first 
subsequent CRP concentration in CR (range 0.0-91.0 mg/L, median 5.11 mg/L). 
This analysis showed that there was no significant difference between PR and CR 
(W=210.0, p=0.28) for each individual dog, which was consistent with the results 
for the whole population in section 3.6.2. 
3.6.4.3  Pre-treatment compared to progressive disease 
To determine whether the CRP concentration differed at time of relapse (PD) 
compared to Pre-Tx when considering individual dogs (Fig. 19), the WSR test was 
repeated for 57 dogs.   
 
Figure 18 Box-and-whisker plot of CRP concentration for individual dogs at pre-treatment 
(Pre-Tx) and time of first relapse (PD).  
 
The CRP concentration at Pre-Tx (range 0.4-184.9 mg/L, median 27.5 mg/L) was 
compared with the CRP concentration at their first subsequent episode of PD 
(range 0.2-294.0 mg/L, median 12.7). This analysis confirmed that there was a 
significant difference between Pre-Tx and PD CRP concentration (W=1172.0, 
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p=0.006) for each individual dog which agreed with the results for the whole 
population. The degree of change was determined for each individual dog and 
most dogs (n=41, 72%) had a lower CRP concentration at PD compared to the CRP 
concentration at time of diagnosis (median % difference -49.2%, range -98.7-
956.1%). Sixteen dogs (28%) dogs however had a higher concentration i.e. they 
exhibited a positive % difference between PD and Pre-Tx.  
3.7 Determining a Diagnostic Threshold for CRP  
 
Although a normal reference range for CRP is available, an AUROC curve was 
generated using the control dogs and dogs with LSA to determine an upper limit 
of CRP concentration (cut-off value) which could potentially be used as a 
diagnostic threshold for LSA (Figure 20).  
 
Figure 19 AUROC curve of healthy control dogs and dogs with LSA 
 
The area under the ROC curve was 0.94 (95% CI 0.9-1.0, p<0.001) indicating that 
CRP has a good ability to discriminate between individuals with LSA and those 
without.  The current recognised upper reference limit for CRP is 10 mg/L and 
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the closest cut-off point in this AUROC curve was 9.5 mg/L. This cut-off had a 
sensitivity of 86.3% (95% CI 76.3-93.2%) and a specificity of 91.5% (95% CI 81.3-
97.2%), with a likelihood ratio of 10.2. A CRP cut-off of 13.7 mg/L gave the best 
balance between sensitivity and specificity based on the AUROC curve results. At 
this threshold sensitivity was 83.6% (95% CI 73.1-91.2%) and specificity was 96.6% 
(95% CI 88.3-99.6%), with a likelihood ratio of 24.7.  The likelihood ratio reached 
its maximum value of 46.9 at a CRP cut-off of 17.3 mg/L, and at this threshold 
although the sensitivity was reduced to 79.5% (95% CI 68.4-88.0%) the specificity 
was increased to 98.3% (95% CI 90.9-100.0%) indicating there would be fewer 
false positives if this cut-off was used. There was 100% specificity at a CRP cut-
off of 30.7 mg/L.  
3.8 Using CRP as a predictor of relapse in LSA 
 
The ideal biomarker for LSA would become elevated prior to relapse of the 
disease i.e. before it was clinically apparent so that earlier therapeutic changes 
could be implemented and the overall survival time for the patient improved. 
The use of CRP as an early predictor of relapse was investigated using both a 
paired t-test and an AUROC curve.  
3.8.1 Does CRP concentration become elevated prior to relapse? 
To determine whether CRP concentration became elevated immediately prior to 
an episode of relapse in individual dogs in our population, the CRP 
concentrations at 2 weeks prior to relapse (PD-2), 1 week prior to relapse (PD-1) 
and at time of relapse (PD) were examined. These data were only available for 
29 dogs (Table 18). To improve the Gaussian distribution and to facilitate the 
use of the parametric paired t-test, CRP was log-transformed (logCRP).  
Table 18 Log-transformed CRP (logCRP) leading up to patient relapse 
Impending relapse group n= LogCRP range (mg/L) 
 
Mean (mg/L) SD 
PD-2 28 -0.32-1.41 0.67 0.45 
PD-1 29 -0.96-2.21 0.82 0.68 
PD 29 0.22-2.47 1.21 0.62 
PD-2 = 2 weeks prior to relapse, PD-1 = 1 week prior to relapse, PD = time of relapse. 
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There was a general trend of CRP concentration becoming elevated over the 3 
weeks, as can be seen in the boxplot in Figure 21. As might be expected, there 
was a significant difference between the mean logCRP concentrations of PD-1 
and PD (T=-3.92, p=0.001) indicating that CRP concentration becomes elevated 
at the point of clinical relapse. However, there was no significant difference 
between the mean logCRP concentration between PD-2 and PD-1 (T=-1.46, 
p=0.16). These results indicate that CRP does not become elevated before the 
point of relapse (i.e. within the time period of 1-2 weeks before relapse) and 
only elevates at the point when relapse is already clinically apparent.  
 
Figure 20 Box-and-whisker plot of CRP concentration at 2 weeks (PD-2) and 1 week (PD-1) 
prior to relapse, and at relapse of disease (PD).  
 
To further investigate whether CRP concentration could guide clinical decision-
making with regards impending relapse, an AUROC curve was generated using 
the CRP concentrations at PD and the CRP concentrations at time of CR as a 
control group (Figure 22).  The area under the ROC curve was 0.73 (95% CI 0.67-
0.78, p<0.0001) which indicates a moderate ability for CRP to discriminate 
between dogs in PD compared to those in CR.  The cut-off value with the best 
balance between sensitivity and specificity was 11.9 mg/L. This level would not 
be particularly useful from a clinical perspective however as the sensitivity was 
only 61.3% (95% CI 51.6-70.4%) and specificity was only 77.7% (95% CI 72.5-
82.3%). The results of this AUROC curve suggest that there is not enough 
difference between CRP concentrations in PD and CR to provide a useful cut-off 
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that could help guide clinical decision making with respect to whether a patient 
may be relapsing.  
 
Figure 21 AUROC curve of CRP concentration at progressive disease (PD) and complete 
remission (CR) 
 
3.9 The prognostic significance of CRP concentration in dogs 
with LSA    
 
To determine whether Pre-Tx CRP held any prognostic significance in dogs with 
LSA, both logistic regression and survival analysis was performed. To remove the 
effect on survival of different treatments and to homogenise the population, 
only the 51 dogs that were given a CHOP or modified CHOP protocol were 
included in the analysis.  
3.9.1 Which patient variables affect OST in dogs with LSA? 
To determine which parameters might affect survival time, different patient 
variables were examined at a univariate level using a logistic regression model 
with different binary outcomes (survival time ≤6 months vs. >6 months, dead vs. 
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alive, death due to LSA vs. death due to other reasons and relapsed vs. not 
relapsed). Continuous variables examined included log-transformed CRP, 
albumin and calcium. Categorical variables included WHO stage (II-III/IV-V), 
substage (a/b), immunophenotype (B-/T-cell), site (multicentric/not-
multicentric), albumin (hypalbuminaemic/not hypoalbuminaemic), calcium 
(hypercalcaemic/not hypercalcaemic) and CRP (≤30 mg/L/>30 mg/L).  
The only significant findings for survival were: 
• WHO substage ‘b’ when compared to substage ‘a’ was 0.22 times (95% CI 
0.07-0.73) more likely to result in an OST ≤6 months (p=0.013). 
• T-cell immunophenotype when compared to B-cell was 0.28 times (95% CI 
0.08-0.99) more likely to result in an OST ≤6 months (p=0.05).   
Multivariate logistic regression analysis using the significant variables from the 
univariate analyses was performed and WHO substage retained significance with 
substage ‘b’ being 0.13 times (95% CI 0.03-0.56) times more likely to result in an 
OST ≤6 months (p=0.006).  
Kaplan-Meier (KM) survival curves were generated for both patient variables 
significant on univariate analysis, and confirmed the significant differences in 
overall survival time (OST) for both immunophenotype and substage for those 
dogs treated with a CHOP-type protocol (Figure 23). Dogs were censored at the 
date of analysis if they had not died. Dogs with B-cell LSA had a median OST of 
330 days compared to just 136 days for dogs with T-cell LSA (LR test p=0.0008, 
GBW test p=0.003), and the hazard ratio was 0.31 (95% CI 0.15-0.61). Dogs with 
substage ‘a’ had a median OST of 297 days compared to just 92 days for dogs 
with substage ‘b’ (LR test p=0.004, GBW test p=0.002), and the hazard ratio was 
0.53 (95% CI 0.29-0.98). 
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Figure 22 Kaplan-Meier survival curves for overall survival time and the results of curve 
comparison for i) immunophenotype and ii) WHO substage 
 
3.9.2 Which patient variables affect time to first relapse (TFR) in 
dogs with LSA? 
Further analysis of variables affecting period of remission revealed that the TFR 
was significantly different between the dogs with B-cell and T-cell 
immunophenotypes that were treated with a CHOP-type protocol (Figure 24). 
Dogs were excluded if they had died before a first relapse was reached and dogs 
were censored at the date of analysis if they had not reached the first relapse 
point. The median TFR was 270 days for dogs that had B-cell LSA and was 126 
days for dogs that had T-cell LSA (LR test p=0.03). The hazard ratio was 0.41 
(95% CI 0.18-0.93). No other variables significantly affected TFR. 
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Figure 23 Kaplan-Meier survival curve for time to first relapse and the result of the curve 
comparison for immunophenotype 
 
3.9.3 CRP elevation categories and overall survival time 
Although absolute pre-treatment CRP concentration did not significantly affect 
survival by logistic regression, the different CRP elevation categories (normal, 
mild, moderate and marked) were also examined with respect to OST using KM 
survival curves (Figure 25). The outcome was days to death, and dogs were 
censored at time of analysis if they were still alive. The median survival times 
for each group differed (Table 19), but comparison of the curves with the LR test 
showed there was no statistically significant difference between the groups 
(p=0.71). 
Table 19 Median survival times from the Kaplan-Meier survival curves of the different CRP 
elevation categories 
CRP elevation group n= Median survival time (Days) 
Normal 5 198 
Mild 17 249 
Moderate 24 123 
Marked 5 328 
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Figure 24 Kaplan-Meier survival curves of overall survival time of CRP elevation categories 
for dogs on a CHOP-type protocol 
 
To increase the number of dogs in the groups, the KM survival curves were 
repeated by combining the dogs in the normal and mild CRP categories and those 
in the moderate and marked CRP categories (Figure 26). This resulted in 2 
groups of dogs for analysis: those with pre-treatment CRP concentrations ≤30 
mg/L (n=22) and those with pre-treatment CRP concentrations >30 mg/L (n=29).   
 
Figure 25 Kaplan-Meier survival curve of overall survival time of dogs on a CHOP-type 
protocol with a CRP concentration 0-30 mg/L and >30 mg/L 
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The dogs in the ≤30 mg/L CRP group had a longer median survival time of 243 
days compared to the dogs in the >30 mg/L CRP group who had a median survival 
time of 153 days, however significance was not reached when comparing the 2 
curves using the LR test (p=0.91) and the GBW test (p=0.36).  
3.9.4   CRP elevation categories and time to first relapse 
To determine if any significant differences existed between the 2 CRP groups 
(CRP ≤30 mg/L [n=17], CRP >30 mg/L [n=20]) with regards TFR, KM survival 
curves were repeated for 37 dogs (Figure 27) with the outcome being the time in 
days from the start of treatment to when the patient relapsed. Patients were 
censored if they had not reached a first relapse by the time of analysis and dogs 
that died prior to relapsing were excluded from analysis.  
 
Figure 26 Kaplan-Meier survival curve for time to first relapse for dogs with a CRP 
concentration 0-30 mg/L and >30 mg/L 
 
The dogs in the ≤30 mg/L CRP group had a shorter median time to first relapse 
of 146 days compared to the dogs in the >30 mg/L CRP group (median TFR 242 
days), however, significance was not reached when comparing the 2 curves using 
the LR test (p=0.42) or GBW test (p=0.70). 
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4 Discussion 
4.1 Study aims 
 
The aim of this longitudinal study was to investigate whether the acute phase 
protein CRP was a useful serum biomarker in dogs with LSA. The following points 
were examined and are discussed in more detail below: 
1. How CRP concentration differs between dogs with LSA and normal healthy 
dogs. 
2. The clinical parameters which affect CRP concentration at time of 
diagnosis in dogs with LSA. 
3. How CRP concentration changes in dogs with LSA once treatment with 
chemotherapy is initiated. 
4. How CRP concentration changes with different remission statuses and 
whether CRP can be used to predict relapse of LSA.  
5. The prognostic significance of pre-treatment CRP concentration in dogs 
with LSA that have been treated with a CHOP-type chemotherapy 
protocol.  
4.2 Discussion of results 
 
4.2.1 CRP concentration in dogs with LSA 
4.2.1.1 LSA dogs compared to healthy controls 
This study of dogs with LSA confirmed that the median CRP concentration is 
elevated in this group of animals when compared to a healthy control group. As 
previously reported (Nielsen et al., 2007, Tecles et al., 2005), there was marked 
variability in CRP concentration in the dogs with LSA. The majority of control 
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dogs (92%, 54/59) had serum CRP concentrations within the normal reference (0-
10mg/L) however the majority of dogs with LSA (86%, 63/73) had serum CRP 
concentrations above the normal reference. The CRP concentration can become 
markedly elevated in dogs with LSA, and a maximum 27-fold increase (273.7 
mg/L) above reference was observed in this study, though most dogs (89%, 
65/73) had less than a 10-fold increase which was consistent with earlier studies 
(Tecles et al., 2005, Nielsen et al., 2007, Mischke et al., 2007). As observed 
previously (Mischke et al., 2007, Tecles et al., 2005, Nielsen et al., 2007), not all 
dogs with LSA exhibited an elevation in CRP concentration and 14% (10/73) of 
dogs in this study had pre-treatment serum CRP concentrations that were within 
the normal reference range. The dogs with normal CRP concentrations presented 
with obvious gross disease and a variety of clinical signs, and all WHO stage and 
substage groups were represented. It was therefore unclear as to why these dogs 
did not have an elevated CRP concentration like the other dogs. CRP is a 
sensitive marker of inflammation and tissue injury and levels can fluctuate in 
response to insult within hours (Caspi et al., 1984). This study suggests however 
that the mechanism of inflammation in LSA is not simple and that CRP expression 
is very variable in dogs with this disease. It is currently unclear why some dogs 
do not appear to mount an inflammatory response despite the presence of gross 
disease and I propose that there may be a relationship between absolute gross 
tumour volume and the inflammatory response, and that there may be a critical 
threshold which must be exceeded before CRP concentration increases. The 
elevations in CRP may be as a direct consequence of the ischaemic damage to 
local tissues by lymphadenomegaly or may also be a consequence of the release 
of interleukin-6 (IL-6) from neoplastic B-cells (Kato et al., 1996). IL-6 
concentration is elevated in human patients with LSA prior to treatment, and 
the degree of elevation is associated with the presence of clinical symptoms in 
this disease, a poorer response to treatment and reduced TFR and OST (Preti et 
al., 1997, Wieland et al., 2003, Legouffe et al., 1998, Gaiolla et al., 2011). It 
would be reasonable to suspect that elevated IL-6 causes similar consequences 
in the canine patient with LSA. Further investigation including measuring the 
levels of the cytokines that are known to drive CRP production such as IL-1, IL-6 
and TNF-α may determine whether it is their levels which are contributing to the 
magnitude of the APR and hence the variability of serum CRP concentration. It 
should be noted however that recent investigation into TNF-α in dogs with LSA 
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has suggested that this cytokine has limited value as a tumour marker (Hofer et 
al., 2011).  
The 5 dogs from the LSA population that were identified as being outliers with 
extreme elevations in CRP concentration were all diagnosed as having WHO 
Stage IV-V substage b multicentric LSA. Four of the 5 dogs (80%) had marked 
hepatic involvement with LSA, and indeed euthanasia was recommended for one 
patient due to the degree of hepatic damage that was present.  Interestingly 
only 1 of the outlier dogs went on to receive chemotherapy treatment, with the 
owners of 3 of the dogs opting for euthanasia at time of diagnosis and one owner 
opting for palliative prednisolone followed rapidly by euthanasia. This may 
suggest that these dogs with extremely elevated CRP presented with worse 
clinical signs than other patients which encouraged clients to choose euthanasia 
over treatment, however other reasons for euthanasia could have included 
financial constraints or personal ethical beliefs of using chemotherapy to treat 
animals. The presence of such marked CRP production in the face of hepatic 
damage shows that the APR can still occur in dogs with infiltration of the liver, 
and perhaps that the liver is not the only site of APP production in these 
patients.  
There was a large degree of variation in serum CRP concentration observed not 
only in the dogs with LSA (both at time of diagnosis and throughout the course of 
treatment) but also within the group of healthy control dogs which has been 
previously reported in dogs with LSA (Nielsen et al., 2007) and in client-owned 
healthy dogs (Carney et al., 2011). Despite most laboratory populations showing 
CRP concentrations within the normal reference range (Kuribayashi et al., 2003, 
Merlo et al., 2007), very variable concentrations of CRP have been reported 
exceeding the upper reference limit in at least one study involving a controlled 
laboratory population of dogs (Otabe et al., 1998).  The elevation observed in 
our client-owned dogs may be due to the fact that, unlike laboratory animals, 
these dogs do not live in a strictly regulated environment and are exposed to a 
multitude of environmental insults which could stimulate the APR such as sub-
clinical trauma, gastro-intestinal disturbances and infections. A relationship 
between increased serum CRP and exercise has been shown (Wakshlag et al., 
2010) though this study looked at sled-dogs that were exposed to extreme levels 
of exercise and it is unclear what effect more modest levels of exercise would 
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have had on CRP production in our population of control dogs. These findings 
suggest that a standardised reference range may not be suitable, as clearly dogs 
can both exhibit an increased CRP concentration when there is no detectable 
disease present and exhibit a normal CRP concentration when there is a known 
disease present. Due to the variability of serum CRP, it has been suggested that 
an individual patient-centred baseline may be more appropriate and that 
multiple measurements of CRP concentration over time may prove more 
clinically relevant than a single absolute value (Kjelgaard-Hansen et al., 2003b). 
I believe that the degree of change in CRP concentration within a patient rather 
than the absolute change may be significant, however a much larger study 
cohort with greater homogeneity with regards clinical presentation and 
pathological diagnosis would be required to investigate this hypothesis.  
4.2.1.2 The use of CRP concentration to aid diagnosis of LSA 
The ability of CRP concentration to aid diagnosis of LSA was investigated by 
means of an AUROC curve (generated using the CRP concentrations from the 
control group and from the dogs with LSA at time of diagnosis). The AUROC 
curve indicated that CRP concentration has a good ability to discriminate 
between individuals with LSA and those without, and 13.7 mg/L was the cut-off 
CRP concentration with the best balance between sensitivity (83.6%) and 
specificity (96.6%). This cut-off is only just above the published upper reference 
limit for CRP (Eckersall et al., 1989) and reflects the fact that many of the dogs 
with LSA in our study had normal or only mild elevations in CRP concentration at 
time of diagnosis. To test the cut-off value obtained from the AUROC curve it 
should have been possible to calculate the positive and negative predictive 
values using CRP concentrations obtained from other control dogs and dogs 
known to have LSA or other diseases. However, this was not possible within the 
limits of this study due to a lack of availability of further control samples and 
samples from dogs with known diseases, including LSA.   
Other researchers have found CRP useful in diagnosing LSA. CRP is currently 
included in a commercial proteomic assay which has been developed using 
chromatography and mass spectrometry to identify the serum protein fingerprint 
of dogs that have LSA (PetScreen Ltd, UK). During the development of this assay 
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13 protein peaks were identified that differed significantly between dogs with 
and without LSA, with 2 of these peaks specifically capable of differentiating 
between the 2 groups of dogs. One of these protein peaks has since been 
identified as being the positive APP haptoglobin (Hp); the second is still under 
investigation. To improve the performance of a single biomarker alone, the 
PetScreen Ltd assay combines different biomarkers, currently the APPs Hp and 
CRP. Results from 194 test samples have provided encouraging results with an 
assay sensitivity of 75-85% and a specificity of 91-93%, with a negative predictive 
value of 88-93% and a positive predictive value of 80-86% (Ratcliffe et al., 2009, 
PetScreen Ltd, 2012). Although this assay has been marketed as an early 
diagnostic test which should be used when a dog first presents with enlarged 
lymph nodes, the assay does not have 100% sensitivity and specificity and 
therefore a suspected diagnosis should always be confirmed by cytological or 
histopathological methods. These allow a definitive diagnosis to be made with 
specific classification of the type of LSA, and can offer information regarding the 
grade and immunophenotype which may guide therapeutic options and provide 
prognostic information (Ponce et al., 2004, Marconato, 2011, Marconato et al., 
2011, Williams et al., 2008). 
4.2.2 The relationship between CRP concentration and LSA 
patient variables 
4.2.2.1  Pre-treatment albumin 
The concentration of the negative acute phase protein albumin had a modest 
but significant inverse correlation with log-transformed CRP (logCRP) 
concentration in our group of dogs with LSA. Similar findings have been reported 
in humans with lymphoid neoplasia and have been shown to have prognostic 
significance (Elahi et al., 2005, Nakamura et al., 2008). The median albumin 
concentration was significantly lower in dogs with WHO stage IV-V and substage 
‘b’ compared to dogs with WHO stage II-III and substage ‘a’, however it is worth 
noting that the median albumin concentration of dogs with stage IV-V and 
substage ‘b’ was only just below the lower reference limit of 29 g/L. Univariate 
analysis using logistic regression with CRP concentration as a binary outcome 
(≤30 mg/L and >30 mg/L) showed that hypoalbuminaemia was a significant 
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predictor and was 2.74 times (95% CI 1.057-7.18) times more likely to result in a 
CRP concentration >30 mg/L when compared to non-hypoalbuminaemic dogs 
with LSA. Hypoalbuminaemia can arise in dogs with LSA for a myriad of reasons 
including as a direct consequence of intestinal or renal involvement resulting in 
protein loss (Dossin and Lavoué, 2011, Bryan et al., 2006), from chronic anorexia 
causing malnutrition and protein catabolism (McMillan, 2009), and from hepatic 
involvement causing reduced production of the plasma proteins (Dank et al., 
2011, Hoskins, 2005, Balkman, 2009, Gruys et al., 2005). In humans, it has 
recently been hypothesised that the reduction in the negative APPs, which 
includes albumin, is affected more greatly by the APR than the nutritional state 
(Fuhrman et al., 2004, McMillan, 2009). Most of the 15 dogs that had a more 
moderate to marked hypoalbuminaemia (defined here as an albumin 
concentration ≤24 g/L) presented either with chronic diarrhoea, hepatic 
infiltration including marked hepatic disease as observed by elevated liver 
enzymes, and/or a history of anorexia and weight loss. The significant negative 
correlation with logCRP suggests there is an inverse relationship between the 
negative APP albumin and the positive APP CRP, likely due to the activation of 
the APR which causes altered mobilisation of the amino acids by the liver 
(Kushner, 1982, Gabay and Kushner, 1999, Ebersole and Cappelli, 2000, 
Nakamura et al., 2008). However, the low R2 (13.92%) for the model implies that 
CRP is not the only driver of albumin levels in these dogs, and it would seem 
reasonable that the reduction in albumin concentration in our population was 
also as a direct consequence of the disease.   
4.2.2.2  Clinical stage of LSA 
The association between cancer and the APR has been widely investigated and a 
positive correlation between CRP concentration and both the clinical stage of 
lymphoid neoplasia and the presence of clinical signs at time of diagnosis has 
been reported for humans (Wieland et al., 2003, Herishanu et al., 2007, 
Legouffe et al., 1998, Khalifa et al., 2008). However, to date this has not been 
reported for dogs. Univariate analysis with linear regression revealed a 
significant positive relationship between logCRP concentration at time of 
diagnosis and WHO stage and substage, though this relationship was only present 
when grouped stages II-III were compared to stages IV-V, with no significant 
   
 
93
difference determined when comparing the 2 lower stages (II and III) to each 
other and the 2 higher stages (IV and V) to each other. Following multivariate 
analysis, WHO stage was the only variable which retained significance with 
stages IV-V having a significantly increased concentration of logCRP compared to 
stages II-III. Logistic regression using CRP concentration as a binary outcome (≤30 
mg/L and >30 mg/L) instead of an absolute concentration, also revealed WHO 
stage and substage to be significant categorical predictors, and once again on 
multivariate analysis WHO stage retained significance with stages IV-V 4.07 times 
(95% CI 1.11-14.99) more likely to result in a CRP concentration >30 mg/L when 
compared to stages II-III. The significant relationship between WHO stage, and to 
a lesser degree substage, in this population of dogs with LSA suggests that in this 
disease the APR is influenced by clinical status of the animal rather than merely 
just the underlying primary disease. Dogs with advanced WHO stages of disease 
tend to have heavier tumour burden and grossly enlarged lymph nodes which 
cause ischaemic damage to surrounding tissue with localised inflammation. The 
rapid growth of the tumour results in high cell turnover and constant death of 
neoplastic cells which release cytokines. Tumour cells can also produce 
chemokines that attract local inflammatory cells such as macrophages and 
neutrophils (Coussens and Werb, 2002). These inflammatory cells secrete 
cytokines including interleukins IL-1, IL-6 and TNF-α into the blood which induce 
the hepatocytes to secrete the APPs, such as CRP (Coussens and Werb, 2002, 
Gruys et al., 2005).  This study only had a small number of dogs in the lower 
WHO stage groups and didn’t include any dogs with stage I disease; also the 
exact quantity of tumour burden was not available. A larger cohort containing 
more dogs with lower WHO stages, and an accurate assessment of tumour 
burden using advanced imaging modalities such as computed tomography would 
be required to determine if there were significant differences between the 
individual WHO stages and whether tumour burden had a significant relationship 
with serum CRP concentration.  
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4.2.3 Changes in CRP concentration in dogs receiving 
chemotherapy 
4.2.3.1  CRP concentration following treatment initiation 
The change in CRP concentration between week 0 (pre-treatment) and week 4 of 
treatment was investigated in 41 dogs that exhibited some degree of response to 
treatment with chemotherapy (i.e. had achieved PR or CR). Of these dogs, 34 
(87%) had a pre-treatment CRP above reference. Following induction of a 
chemotherapy protocol, the majority of dogs (83%) that had had a response to 
treatment had a CRP concentration within the normal reference limit.   
These results suggest that treatment with chemotherapy causes normalisation of 
CRP concentration in most dogs by week 4 of treatment. The effect on CRP 
concentration by the actual chemotherapy agents administered, and from the 
glucocorticoids that were also included in the protocols, could not be quantified 
in these dogs due to the variability in chemotherapy protocols used and the 
timing of samples. Previous studies investigating the effect of chemotherapy and 
prednisolone on healthy dogs have suggested that these agents do not affect 
serum APP concentrations (Ogilvie et al., 1993, Merlo et al., 2007, Martínez-
Subiela et al., 2004) and it would be reasonable therefore to suspect that the 
reduction of CRP in these dogs was directly related to the reduction in tumour 
size rather than being treatment-mediated.  
4.2.3.2  CRP concentration and remission status 
There was marked variation in CRP concentration and overlap of the range of 
concentrations at time of diagnosis (Pre-Tx) and at each remission status, which 
supports the current literature (Nielsen et al., 2007). The widest spread of CRP 
concentrations was found for Pre-Tx and progressive disease (PD) indicating the 
results were most variable for dogs in these states. When examining the 
differences that existed between the remission statuses with the pooled samples 
from all dogs, median CRP concentration in the control population and at time of 
diagnosis (Pre-Tx) was significantly different when compared to CR, PR and PD. 
Median CRP concentration also differed between CR and PD, and PR and PD. 
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There was no significant difference between the median CRP concentration of 
dogs in CR and PR. 
To determine if these differences still existed when considering individual dogs, 
comparison of the CRP concentrations at Pre-Tx with their first subsequent CRP 
concentration at CR (after week 4 of treatment), and comparison of the CRP 
concentration at PR with their first subsequent CRP concentration at CR was 
performed on matched samples from individual dogs. The results from these 
analyses were in agreement with the results from the analysis of the pooled 
samples.  
The lack of significant difference between the median CRP concentration for CR 
and PR was interesting. Dogs in PR are still showing signs of gross clinical disease 
and by definition ‘PR’ indicates that the tumour has shrunk by >30% but <100% 
(Eisenhauer et al., 2009). One would therefore expect there to be a higher CRP 
concentration in dogs in PR compared to those in CR (where there is no gross 
clinical disease present). This finding suggests that despite the presence of 
disease in PR, the tumour burden has decreased enough to reduce the degree of 
local inflammation and ischaemia. Consequently, there is minimal activation of 
the APR and reduced production of CRP.  
The results of the pooled and paired analyses suggest that there are significant 
differences present between the median CRP concentrations of the different 
remission groups (except between CR and PR) which are in agreement with the 
current literature (Nielsen et al., 2007). However, there are often only subtle 
differences as observed by the overlap of the ranges of CRP concentration in the 
different groups. This indicates that CRP would not be a useful biomarker to 
discriminate between the different remission statuses and could not aid clinical 
decision making with regard to categorising patients following treatment with 
chemotherapy. 
4.2.3.3  CRP concentration at time of relapse of LSA 
The pooled analysis revealed a significant difference between the median CRP 
concentrations in the Pre-Tx group compared to PD group. Comparison of 
individual dogs’ pre-treatment CRP concentration with their first subsequent 
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relapse (PD) CRP concentration again revealed that a significant difference 
exists. In the majority of dogs (72%), the CRP concentration was lower at the 
point of relapse compared to the time of diagnosis.  
The fact that CRP concentrations at time of diagnosis were not the same as 
those obtained at time of relapse could be because relapse is often detected 
much more rapidly than when the disease is initially diagnosed, as patients are 
being more closely monitored. Consequently, the degree of tumour burden at 
this time is often much less than it is at the time of diagnosis. The fact that 28% 
(16/57) of dogs had a higher relapse (PD) CRP concentration compared to their 
Pre-Tx value however suggests that the response of individual dogs is very 
variable. There is also the possibility that for these dogs with elevated CRP 
concentration at relapse, in addition to clinically detectable peripheral disease, 
there may have been internal gross disease. This degree of disease is usually not 
quantified by diagnostic imaging techniques due to financial constraints and the 
fact that it generally would not change the clinical outcome.  These findings 
again suggest that there may be a relationship between tumour burden and CRP 
concentration which warrants further investigation and indeed, it has been 
suggested in patients with NHL that tumour burden could be used as a prognostic 
factor (Gobbi et al., 2004). I propose that there may be a minimum threshold for 
tumour volume which must be exceeded before the APR is activated which 
would account for the variance in CRP concentration at time of diagnosis and 
relapse.  
4.2.4 CRP as a predictor of relapse 
CRP has a moderate ability to discriminate between dogs with CR and PD, and a 
cut-off value of 10.7 mg/L was deemed suggestive of relapse following AUROC 
curve analysis. This cut-off value was only just above the upper reference limit 
for CRP concentration, and there was poor balance between sensitivity (60.7%) 
and specificity (73.3%), suggesting it would not be useful in a clinical setting.  
The role of CRP as a predictor of relapse was more closely examined using 
matched samples from individual dogs. The ranges of CRP concentration at 3 
time points (2 weeks prior to relapse, 1 week prior to relapse, and point of 
clinical relapse) showed marked overlap, and the only significant difference 
   
 
97
between these 3 time points occurred between the mean logCRP concentrations 
at 1 week prior to relapse and time of relapse. This suggests that the CRP 
concentration becomes elevated at the point of relapse but does not increase 
significantly in the weeks immediately leading up to that point, which adds 
further weight to the suggestion that CRP production is mediated directly by the 
tumour and that a certain volume of gross disease is required before an 
elevation in this biomarker is apparent. These findings imply that CRP is not a 
useful biomarker for the early prediction of relapse of disease in LSA which 
agrees with the earlier findings by Nielsen et al (2007). 
4.2.5 CRP concentration and prognosis of LSA 
In human medicine the presence of a systemic inflammatory response and the 
magnitude of that response, as observed by CRP elevation, has been shown to 
predict the duration of cancer-specific and non-cancer disease survival in a 
variety of solid tumours and lymphoid neoplasia (McMillan et al., 2001, Elahi et 
al., 2005, Shimada et al., 2003, Falconer et al., 1995, Beer et al., 2008, 
Karakiewicz et al., 2007). In this study CRP was not predictive of survival or TFI, 
neither as a continuous variable (i.e. log-transformed CRP), nor as a categorical 
variable (i.e. CRP concentration ≤30 mg/L or >30 mg/L). The median survival 
time was shorter for those dogs in the CRP >30mg/L group compared to those in 
the ≤30 mg/L group; however this difference was not significant. These initial 
findings suggest that a difference in survival may exist between dogs with 
moderately and markedly elevated CRP concentrations and it is possible that the 
lack of significance in survival reflects the small number of dogs in each of these 
groups. Further analysis with a larger sample size is needed to confirm or refute 
this suspicion.  
There are many human studies that have shown survival advantages for those 
patients that present with a normal CRP concentration over those that present 
with an elevated CRP concentration in a variety of tumours (Beer et al., 2008, 
Crozier et al., 2007, Shimada et al., 2003, Hashimoto et al., 2005, Yoshida et 
al., 2008); however there is currently no veterinary literature with similar 
findings. Ideally, any future studies looking at CRP concentration with regards to 
OST in dogs with LSA, would include enough dogs with pre-treatment CRP 
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concentrations in the normal range to allow for comparison with dogs with 
elevated CRP concentrations.  
4.2.6 Negative prognostic indicators for LSA in this study 
The presence of clinical signs at diagnosis (i.e. being classified as WHO substage 
‘b’) and the T-cell immunophenotype were shown to be significant negative 
predictors of OST in this study of dogs with LSA. Other patient variables 
including WHO stage, site of disease, albumin concentration and calcium 
concentration were not found to have any prognostic significance.  
It is generally accepted that WHO substage and immunophenotype carry 
prognostic significance (Keller et al., 1993, Kiupel et al., 1999, Baskin et al., 
2000, Dobson et al., 2001, Marconato et al., 2011). However, there is a degree 
of disparity in the literature as to what other prognostic factors are significant, 
with some authors suggesting that increased WHO stage, the presence of 
hypercalcaemia at time of diagnosis and previous treatment with steroids carries 
a poorer prognosis (Jagielski et al., 2002, Gavazza et al., 2009, Kaiser et al., 
2007).  
In human medicine, the traditional primary method for assessing prognosis for 
NHL was to consider the Ann Arbour stage, which is similar to the WHO staging 
system used in dogs with LSA. This system alone was found to be inadequate at 
predicting survival and therefore the International Prognostic Index (IPI) was 
developed. This considers a range of clinical parameters to predict patient 
outcome more accurately including age, sex, Ann Arbour stage, LDH 
concentration, performance status and the number of extranodal sites of 
disease. Using a point system for each of the risk factors, the sum of the points 
assigned to each risk factor correlates with a risk group which provides a 
predicted 5 year survival rate (The International Non-Hodgkin's Lymphoma 
Prognostic Factors Project, 1993, Hermans et al., 1995). Some veterinary 
researchers are also moving towards considering a panel of different patient 
variables to predict more accurately remission period and survival time 
(Marconato et al., 2011). 
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4.2.7 Other possible serum biomarkers for canine LSA and their 
clinical relevance 
4.2.7.1  Serum biomarkers reported in the veterinary literature 
The ability of other serum biomarkers to predict disease relapse has been 
investigated in dogs with LSA. Those shown to have the greatest clinical 
potential include serum TK, AGP and LDH. TK is a cytoplasmic enzyme which 
catalyses the phosphorylation of thymidine to thymidine monophosphate and 
exists in two forms: cytoplasmic thymidine kinase 1 (TK-1) and mitochondrial 
thymidine kinase 2 (TK-2). TK-1 is associated with cellular proliferation and may 
be of clinical relevance in dogs with LSA as this disease is characterised by a 
very high rate of proliferation which is reflected in the levels of TK-1 (von Euler 
and Eriksson, 2011). Serum TK levels are elevated in dogs with LSA, and 
concentration normalises once remission of disease is achieved (von Euler et al., 
2004, Nakamura et al., 1997, Elliott et al., 2011). AGP is a glycosylated protein 
which is a positive APP which behaves in a similar way to CRP in dogs with LSA. 
Its concentration is often elevated at time of diagnosis and at relapse of disease, 
and normalises once remission has been achieved (Ogilvie et al., 1993, Hahn et 
al., 1999). Serum concentrations of both serum TK and AGP have been shown to 
become elevated at least 3 weeks prior to relapse of disease becoming clinically 
evident (Hahn et al., 1999, von Euler et al., 2004). LDH is a glycolytic enzyme 
which catalyses glycolytic metabolism by converting lactate to pyruvate, and is 
expressed as 5 isoenzymes. LDH is elevated in dogs with LSA, specifically the 
isoenzymes LDH2 and LDH3 (Zanatta et al., 2003, Nakamura et al., 1997, 
Marconato et al., 2009, Marconato et al., 2010). The predictive ability of LDH 
was revealed in one study, where dogs with LSA that had elevated LDH 
concentrations at the end of treatment or 1 month after completion of 
chemotherapy were more likely to relapse within a 45 day period than those 
dogs with a normal LDH concentration at the same time points (Marconato et al., 
2010). Showing similarities to CRP, serum TK and LDH concentrations show 
marked variance in dogs with LSA, and their concentrations are not elevated in 
all dogs (Elliott et al., 2011, Nakamura et al., 1997). This suggests that the 
mechanism for the expression of these enzymes is not fully understood in this 
complex disease. 
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Some of the biomarkers that may be useful in predicting early relapse of LSA 
may also have prognostic significance, and it has been hypothesised that 
elevated concentrations of serum TK and LDH at time of diagnosis result in 
reduced disease-free interval (DFI) and OST. However, there is currently 
disparity in the literature and further investigation is required (Elliott et al., 
2011, von Euler et al., 2004, Zanatta et al., 2003, Marconato et al., 2010). It has 
been suggested by several authors that the presence of anaemia (described as a 
haematocrit count ≤35-40%) at time of diagnosis is a negative prognostic 
indicator in dogs with LSA (Abbo and Lucroy, 2007, Marconato et al., 2011, Miller 
et al., 2009). Unlike serum TK and LDH, the haematocrit is routinely measured 
at initial presentation as part of the clinical staging of the patient and may 
prove an easy and inexpensive biomarker to use in general practice. This 
evidence would suggest that these serum biomarkers may be useful in the 
prediction of patient outcome and disease monitoring in dogs with LSA, however 
further validation is required before serial monitoring would be implemented 
into routine clinical practice. 
Some serum biomarkers which have been shown to have some clinical relevance 
in human patients with LSA are also currently under investigation in veterinary 
science. These include the pro-angiogenic molecules matrix metalloproteinases 
(MMPs), and the cytokine, vascular endothelial growth factor (VEGF). 
Angiogenesis plays an important role in the pathophysiology of solid tumours and 
haematologic malignancies such as LSA, and circulating levels of MMP 2 and 9 
and VEGF have been shown to be overexpressed in dogs with LSA. Increased 
levels of these factors correlate with poor response to treatment and a poor 
prognosis, both with respect to DFI and OST (Gentilini et al., 2005, Aresu et al., 
2012). VEGF also appears to correlate with the degree of malignancy of LSA in 
dogs (Zizzo et al., 2010).  High mobility group box 1 (HMGB1) protein is a nuclear 
chromosomal protein found in nearly all cells. It is a cytokine which is secreted 
by activated macrophages and monocytes, and mediates the response to injury, 
infection and inflammation (Lotze and Tracey, 2005). Overexpression of HMGB1 
is associated with the hallmarks of cancer, including angiogenesis, evasion of 
programmed cell death, and limitless replicative ability (Tang et al., 2010). 
HMGB1 concentration is significantly higher in dogs with LSA when compared 
with control dogs. Its concentration reduces in dogs with LSA which are treated 
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with chemotherapy, and early results indicate that levels may be lower in dogs 
which have achieved CR compared to those which have achieved PR (Meyer et 
al., 2010). Monocyte chemotactic protein 1 (MCP1) stimulates myeloid cells from 
the bone marrow and is a cytokine which recruits monocytes, and other cells 
such as neutrophils and NK cells, to sites of inflammation, injury and infection 
(Yadav et al., 2010, Melgarejo et al., 2009). A recent study by Perry et al (2010) 
investigating this protein, showed that serum levels are significantly elevated in 
dogs with LSA when compared to a control group. It has been suggested by the 
authors that an increased concentration of MCP1 in conjunction with elevated 
circulating concentrations of monocytes and neutrophils may be associated with 
poorer DFI for dogs receiving cytotoxic therapy. Finally, circulating tumour-
derived DNA has been quantified in the plasma of dogs with LSA and the levels 
were significantly increased in this disease when compared to healthy dogs 
(Schaefer et al., 2007). The levels of plasma DNA have a potential prognostic 
significance and it has been shown that those dogs with higher concentrations 
have shorter remission periods than those dogs with lower concentrations 
(Schaefer et al., 2007).  
Despite promising early results for these serum biomarkers, they are currently 
only available for quantification in research laboratories, and therefore can not 
currently be applied in general practice.  
4.2.7.2  Serum biomarkers warranting future investigation 
In human medicine, the human leukocyte antigen (HLA) class 1 molecule beta-2 
microglobulin (β2M) has been investigated in patients with LSA. β2M is a 
primitive immunoglobulin which is involved in the immune response. Serum β2M 
is elevated in people with LSA, and its concentration drops following treatment 
with chemotherapy (Child et al., 1980, Bien and Balcerska, 2009, Johnson et al., 
1993). It has been proposed that persistent elevations reflect resistant or 
partially responsive disease (Child et al., 1980). β2M appears to have prognostic 
significance with levels of this molecule allowing the accurate separation of NHL 
patients into low-, medium- and high-risk categories (Avilés et al., 1992). 
Findings from another study showed that there was a greater proportion of 
patients with a 6-year remission rate who had a normal concentration of β2M at 
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time of diagnosis when compared to those with elevated concentrations of β2M 
(Johnson et al., 1993). This molecule has been examined in conjunction with 
other serum biomarkers including CRP and LDH, and the presence of increased 
concentrations across multiple markers have been found to be correlated with 
the presence of bulky disease, b-symptoms and advanced stage and hepatic 
infiltration (Johnson et al., 1993, Bien and Balcerska, 2009). To date, there are 
no studies examining this biomarker in canine LSA and unfortunately, there is no 
commercial assay currently available. 
4.3 Study limitations 
 
All dogs in this study had been referred from other veterinary practices, and as 
such, there may have been a bias towards those dogs that had more aggressive 
and advanced disease, and that were exhibiting worse clinical signs of disease. 
This would explain the lack of WHO stage I dogs and the paucity of dogs with 
WHO stage II disease in this cohort. The T-cell immunophenotype was over-
represented and may explain why our median survival times for dogs treated 
with a CHOP-type protocol was less than the established literature (Chun, 2009, 
Garrett et al., 2002, Baskin et al., 2000). There may also have been variability in 
the classification of remission status during the monitoring of dogs on treatment. 
Remission is objectively assessed, and multiple staff members were often 
involved in the treatment of any one case. The classification of remission status 
was made in accordance with the RECIST guidelines v1.1 (Eisenhauer et al., 
2009); however the decision-making process routinely involved the palpation and 
measurement of peripheral lymph nodes only. Abdominothoracic imaging was 
generally only performed to confirm remission status if there was no peripheral 
disease present at time of initial presentation. This may have resulted in a 
potential bias towards more dogs being classified as being in CR when they were 
in fact only in PR. It is generally accepted that there is disparity between the 
classifications of remission status obtained from the measurement of peripheral 
gross tumour volume using calipers when compared to more objective 
assessment techniques such as flow cytometry of lymph nodes to assess 
minimum residual disease (Williams et al., 2005). Currently however, gross 
evaluation of dogs to determine the response to treatment is the standard 
practice within veterinary medicine as repeated imaging is expensive and often 
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difficult to justify to clients for a patient that is clinically well, especially when 
the findings do not often facilitate a change in the treatment protocol.  
A complicating factor in this study was that several dogs with LSA had 
concurrent disease at time of diagnosis. It is not uncommon for dogs with LSA to 
present in this way as many are mature animals and chronic diseases such as 
osteoarthritis and degenerative heart disease are common in older age.  No 
difference was noted in pre-treatment CRP concentration in dogs with LSA that 
presented with a variety of inflammatory compared to non-inflammatory 
concurrent diseases. The elevation of CRP is greater in infectious conditions and 
haematologic neoplasms (including LSA) compared to other chronic conditions 
(Nakamura et al., 2008, Kjelgaard-Hansen et al., 2003a). No dogs with 
concurrent disease were excluded unless they presented with active infection as 
it was felt that the resultant population of dogs with LSA was very typical of the 
general canine LSA caseload and would provide a more accurate investigation of 
the use of CRP as a biomarker in a true clinical setting. Dogs were excluded from 
this study if they had received previous corticosteroid therapy despite initial 
analysis suggesting no significant difference between the median CRP 
concentrations in those dogs on steroids compared to those that were not. A 
study by Martínez-Subiela, Cerón and Ginel (2004) also found no significant 
difference in the CRP concentration in dogs prior to and after administration of 
immunosuppressive doses of prednisolone. However, those dogs were healthy 
and as glucocorticoids are known to cause apoptosis of neoplastic lymphoid cells 
which could result in the release of inflammatory mediators (Schwartzman and 
Cidlowski, 1994, Moalli and Rosen, 1994) it was deemed more robust to exclude 
these dogs from this study.  
The major limitations of this study were that it was retrospective in design and 
that there was a large variation in sample numbers obtained from each patient 
with LSA due to the use of different chemotherapy protocols. Also, samples were 
not obtained at every chemotherapy time point nor at consistent time points 
between patients, and there was no control sample for every time point.  
Another limitation was that many samples had to undergo multiple freeze-thaw 
cycles over several years due to the ongoing modification of the CRP assay used. 
The stability of CRP at -70°C and its ability to withstand multiple freeze-thaw 
cycles has been previously investigated (Aziz et al., 2003, Macy et al., 1997) and 
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our comparison of CRP concentrations over the different freeze-thaw cycles 
confirmed that it was unlikely that significant degradation to the protein had 
occurred which would have resulted in lower values than previously obtained.  
Despite this being the biggest study to be performed investigating serum CRP 
concentration in dogs with LSA, the numbers were still relatively small. The lack 
of homogeneity within the population was also a limitation, however in order to 
increase numbers within the study to facilitate statistical analysis, dogs from all 
WHO stages and substages, sites, grades and immunophenotypes had to be 
included, and indeed it was of interest to see if any of these clinical variables 
had any bearing on CRP concentration.  
4.4 Conclusions  
 
This study has demonstrated that serum CRP concentration is significantly higher 
in dogs with LSA compared to a healthy control population. Serum CRP 
concentration returns to normal in most dogs following initiation of a 
chemotherapy protocol, however a significant difference remains between the 
median CRP concentration in dogs in CR, as judged by LN palpation, and the 
control dogs. The median CRP concentration differs in patients in PD compared 
to those in CR and PR. There is too much variability in CRP concentration within 
each remission group and too much overlap of concentrations to allow it to be 
used to monitor response to treatment or to predict disease relapse.  More 
objective quantification of lymph node size using advanced imaging techniques 
such as CT or PET-CT at time of diagnosis and throughout treatment may help 
determine if there is a relationship between CRP concentration and gross tumour 
volume, which may help explain the variability in CRP concentration. These 
techniques, along with other techniques for assessing minimum residual disease 
such as flow-cytometry or PCR of lymph node aspirates, may also facilitate more 
accurate assessment of remission status and reveal those patients that have 
recrudescence of disease or have refractory disease.  
A significant relationship has been revealed between the CRP concentration in 
dogs with LSA and WHO stage, substage and albumin concentration. A significant 
relationship between pre-treatment albumin and WHO stage and substage has 
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also been revealed. Pre-treatment CRP concentration does not appear to have 
any prognostic significance, though there is a trend for the median survival time 
for dogs with CRP concentrations ≤30 mg/L to be longer than for those with a 
CRP concentration >30 mg/L. These results warrant further investigation with a 
larger cohort of dogs.  
The findings in this study suggest that there are potential clinical applications 
for monitoring serum CRP concentrations in dogs with LSA. Serum CRP 
concentration at time of diagnosis may be of some value, though its use for 
serial monitoring throughout treatment is more questionable due to the 
variability of CRP concentration across the different remission statuses. Rather 
than focussing purely on CRP it would seem reasonable to suggest that future 
work would include the investigation of a panel of serum biomarkers known to 
be useful in LSA such as albumin, haematocrit, TK, AGP and LDH. The use of 
multiple markers may improve the utility of any single biomarker alone. Analysis 
of this panel at different time points including at diagnosis and serially 
throughout treatment may provide greater prognostic information and give 
earlier evidence of impending relapse of disease. This could facilitate treatment 
modifications which would improve the time to first relapse and overall survival 
time for dogs with LSA.  
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 Appendix 1: Chemotherapy protocols   
Table 20 CHOP protocol~ 
        Week   
Drug 1 2 3 4 6 7 8 9 11 13 15 17 19 21 23 25 
*V X  X  X  X  X  X  X  X  
$C  X    X    X    X   
^D/E/M    X        X    X 
#P X X X X    X         
~ Protocol can be modified to include administration of l-asparaginase (400 iu/Kg or 1,000 
iu/m2) up to 1 week prior to week 1 vincristine. 
*V = vincristine (0.7 mg/m2); $C = cyclophosphamide (250 mg/m2); ^D/E/M = doxorubicin (30 
mg/m2)/epirubicin (30 mg/m2)/mitoxantrone (5.5 mg/m2); #P = prednisolone (2 mg/Kg SID 
week 1, 1.5 mg/Kg SID week 2, 1 mg/Kg SID week 3, 0.5 mg/Kg SID week 4). 
 
Table 21 ALP protocol 
                     Week   
Drug 0 3 6 9     12 15 18 21 
L-asparaginase 
(400 iu/Kg or 10,000 iu/m2) 
X 
+/- 
X 
      
Lomustine  
(60-90 mg/m2) 
X X X X X X X X 
Prednisolone^ X X       
^ Prednisolone given as a tapering dose: 2 mg/Kg SID for 2 weeks then 1 mg/Kg SID for 2 
weeks then 1 mg/Kg EOD for 2 weeks 
 
Table 22 Low dose (LD) COP protocol  
  Phase 
 
Drug 
Induction 
Maintenance 
(after 2 
months) 
Maintenance 
(after 6 
months) 
Maintenance  
(after 12 
months) 
Maintenance  
(after 18 
months) 
Maintenance 
(after 21 
months)$ 
  
Drugs given 1 
week in 2 
Drugs given 
1 week in 3 
Drugs given 
1 week in 4 
Drugs given 
1 week in 5 
Drugs given 
1 week in 6 
*V 0.5 mg/m2 0.5 mg/m2  0.5 mg/m2 0.5 mg/m2 0.5 mg/m2 0.5 mg/m2 
#C 
50 mg/m2 
EOD 
50 mg/m2 
EOD  
50 mg/m2 
EOD  
50 mg/m2 
EOD 
50 mg/m2 
EOD 
50 mg/m2 
EOD 
^P 
40mg/m2 
SID for 7 
days then 
20mg/m2 
EOD 
20 mg/m2 
EOD  
20 mg/m2 
EOD 
20 mg/m2 
EOD 
20 mg/m2 
EOD 
20 mg/m2 
EOD 
$
 Protocol stops at 24 months.   
*V = vincristine; #C = cyclophosphamide; ^P = prednisolone. 
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Table 23 DMAC protocol 
        Week*   
Drug 1 2 3 4 
Cytarabine 
(200-300 mg/m2) 
X  X  
Actinomycin-D 
(0.75 mg/ m2) 
X  X  
Melphalan 
(20 mg/m2) 
 X  X 
Dexamethasone 
(0.23 mg/Kg) 
X X X X 
*Continue alternating drugs weekly until patient relapses 
 
Table 24 Chlorambucil and prednisolone protocol for low grade lymphoma 
                 Week   
Drug 1 2 3 4*     
Chlorambucil 
2-4 mg/m2 
SID 
2-4 mg/m2 
SID 
2-4 mg/m2 
EOD 
2-4 mg/m2 
EOD 
Prednisolone 
40 mg/m2 
SID 
20 mg/m2 
EOD 
20 mg/m2 
EOD 
20 mg/m2 
EOD 
*The dose and frequency of chlorambucil and prednisolone is dictated by the response to 
treatment. Treatment is usually given for 6 months after which the dose and frequency of 
the drugs are tapered off.   
 
Table 25 LMP protocol 
                 Week   
Drug 1 2 3 4*     
Chlorambucil 20 mg/m2  20 mg/m2  20 mg/m2  20 mg/m2  
Methotrexate 
2.5-5 mg/m2  
2-3 
times/week 
2.5-5 mg/m2  
2-3 
times/week 
2.5-5 mg/m2  
2-3 
times/week 
2.5-5 mg/m2  
2-3 
times/week 
Prednisolone 
20-25 
mg/m2 EOD 
20-25 
mg/m2 EOD 
20-25 
mg/m2 EOD 
20-25 
mg/m2 EOD 
* Protocol continues until relapse occurs. 
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Appendix 2: Time-series graphs and boxplots 
comparing serum CRP concentrations obtained on 
multiple assays 
1.1 ELISA v’s Mira: Time-series graphs 
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1.2 ELISA v’s Mira: Boxplots 
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2.1 ELISA v’s Pentra: Time-series graphs 
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2.2 ELISA v’s Pentra: Boxplots 
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3.1 Mira v’s Pentra: Time-series graphs 
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3.2 Mira v’s Pentra: Boxplots 
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Appendix 3: Plot of residuals  
i) Log-transformed CRP vs. WHO Stage II-III and IV-V 
 
ii) Log-transformed CRP vs. WHO substage ‘a’ and ‘b’ 
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iii) Log-transformed CRP vs. albumin (g/L) 
 
